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 20S proteasomes are large, multicatalytic N- terminal threonine proteases which 
are tasked with maintaining intracellular homeostasis by the breaking down of mis-folded, 
oxidized, or tagged proteins into small peptides. Proteasomes are essential for cell division 
and differentiation, and proteasome inhibition represents a successful therapeutic strategy 
against cancers. There are two main isoforms of the proteasome, the constitutive 
proteasome and the immunoproteasome. While the constitutive proteasome is emerging 
as a medical rationale for treatment of solid tumors, the immunoproteasome shows 
promise in the treatment of autoimmune diseases such as rheumatoid arthritis. Inhibition 
of both proteasome forms is necessary for the treatment of multiple myeloma, and is 
accomplished by the FDA approved drugs, bortezomib and carfilzomib. While bortezomib 
equally targets each isoform, carfilzomib has nearly six-fold selectivity for the constitutive 
proteasome. Despite the importance of the proteasome in cancer treatment as well as 
carfilzomibs use in the clinic, there remains no crystal structure of the human 20S 
proteasome, and no crystal structure of a proteasome:carfilzomib complex. This hampers 
drug development efforts charged with designing the next generation proteasome 
inhibitors.  
 The present dissertation describes the structural and functional characterization of 
the constitutive proteasome from human, which will facilitate structure-based 
development of novel drugs. Using X-ray crystallography, the 3D structures of the human 
proteasome in an unbound and carfilzomib bound state have been determined to high 
 iii 
 
resolution. The ligand bound structure provides explanations for the chymotrypsin-like 
selectivity of the drug, as well as to its preferential binding to constitutive proteasomes 
over immunoproteasome. The caspase-like sites have closed off S3 binding pockets which 
sterically hamper binding of carfilzomibs P3 phenyl group. Tryspsin-like sites have very 
similar specificity pocket characteristics as chymotrypsin-like sites, however the S1 
pockets are spacious in comparison, and do not provide as many interactions to 
carfilzomibs P1 leucyl group, which may be reflected in the decreased selectivity. 
Chymotrypsin-like subunits have hydrophobic specificity pockets which form van der 
Waals interactions with carfilzomib that favor ligand binding. In particular, the P3 and P4 
positions are found to be important for overcoming the structural rearrangements of 
Met45, α-helix H1, and β-sheets S5 and S6 upon carfilzomib binding.   
 Additionally in this dissertation, high throughput screening techniques were used 
to identify novel proteasome inhibitors. A natural product polyphenol, PPH-1, was 
identified from microbial extracts, and a second natural product, -mangostin, was 
identified from the National Cancer Institute’s library of clinically active compounds.  
The binding of each to the proteasome’s catalytic subunits was confirmed using Western 
Blotting techniques. Finally, the kinetic characterization of a series of compounds with 
dual proteasome and fatty acid synthase are described. The inhibition of multiple enzymes 
by a single drug may decrease the likelihood that diseases such as cancer will develop 
resistance, due to the need to become resistant along multiple pathways.  The structural 
and functional characterization of the human proteasome described herein, now facilitates 





For my daughter and inspiration, Kayli, who spent many of her precious 
summers in the heat of Texas helping me with research. For my parents, Cynthia and 
John Harshbarger, who have been there for me and my siblings through the toughest of 
times, and make every sacrifice to see their children succeed. For my brothers Elijah and 
James, and my sister Santina. They define what family means and I am grateful for all 









 I would like to thank my advisor, Dr. James Sacchettini, for all his guidance and 
support through my graduate career. I’d like to thank my committee member, Dr. Daniel 
Romo, Dr. David Barondeau, and Dr. Tatyana Igumenova, for all their advice through 
the course of my research and encouragement.  
 Thanks to all my lab members and friends for their constant support both in and 
out of the lab and for making my time at Texas A&M University a memorable 
experience. Lastly, I am thankful for to the chemistry department staff, especially Sandy 
Manning, for all their administration help.  
 vi 
 
TABLE OF CONTENTS 
 Page 
ABSTRACT .......................................................................................................................ii 
DEDICATION .................................................................................................................. iv 
ACKNOWLEDGEMENTS ............................................................................................... v 
TABLE OF CONTENTS .................................................................................................. vi 
LIST OF FIGURES ........................................................................................................ viii 
LIST OF TABLES ........................................................................................................... xv 
1. INTRODUCTION .......................................................................................................... 1 
1.1 Protein Degradation .............................................................................................. 1 
1.2 Ubiquitin Proteasome System .............................................................................. 4 
1.3 Proteasomes Assembly and Architecture ............................................................. 6 
1.4 Proteasome Proteolysis ....................................................................................... 11 
1.5 Immune Functions of the Proteasome ................................................................ 14 
1.6 20S Proteasome: Inhibition and Apoptosis ........................................................ 16 
1.7 Classes of Proteasome Inhibitors ....................................................................... 17 
1.8 Clinically Relevant Proteasome Inhibitors ......................................................... 20 
1.9 Proteasome Inhibitors of Individual Active Subunits ........................................ 22 
1.10 Basic Crystallographic Theory ......................................................................... 24 
1.10.1 Introduction to Crystallography ................................................................ 24 
1.10.2 Phase Problem and Molecular Replacement ............................................. 27 
1.10.3 Model Building and Refinement ............................................................... 29 
2. STRUCTURAL STUDIES OF THE HUMAN 20S PROTEASOME ........................ 31 
2.1 Results and Discussion ....................................................................................... 31 
2.1.1 Sequence Alignments .................................................................................. 31 
2.1.2 Purification, Crystallization and Structure Determination .......................... 36 
2.1.3 Architecture of the Human 20S Proteasome Constitutive Core Particle..... 43 
2.1.4  Subunit Post-Translational Processing and Catalytic Residues ............... 50 
2.1.5 Cleavage Preferences of Catalytic Subunits ................................................ 52 
2.2 Materials and Methods ....................................................................................... 53 
2.2.1 Proteasome Purification .............................................................................. 53 
2.2.2 Crystallization of Human 20S Proteasome Constitutive Core Particle ....... 55 
2.2.3 Data Collection, Processing and Structure Determination .......................... 56 
 vii 
 
2.2.4 Bioinformatics Tools ................................................................................... 57 
3. CARFILZOMIB BOUND HUMAN 20S PROTEASOME ......................................... 58 
3.1 Introduction ........................................................................................................ 58 
3.2 Results and Discussion ....................................................................................... 60 
3.2.1 Carfilzomib Binding .................................................................................... 60 
3.2.2 Interactions of Carfilzomib with Proteasome Specificity Pockets .............. 69 
3.2.3 PR-957 Selectivity for Immunoproteasome ................................................ 73 
3.2.4 Predictions of Carfilzomib Interactions with the Immunoproteasome ....... 76 
3.3 Conclusion .......................................................................................................... 82 
3.4 Materials and Methods ....................................................................................... 85 
4. DISCOVERY OF NOVEL PROTEASOME INHIBITORS; HIGH 
THROUGHPUT SCREENING ....................................................................................... 88 
4.1 Introduction ........................................................................................................ 88 
4.2 Results and Discussion ....................................................................................... 90 
4.2.1 National Institute of Health Clinical Collection (NCC) .............................. 90 
4.2.2 Fungus Microbial Extracts; Zygophiala jamaicensis .................................. 98 
4.2.3 Lymphoma Hit Plate Screen...................................................................... 102 
4.3 Conclusions ...................................................................................................... 106 
4.4 Materials and Methods ..................................................................................... 109 
4.4.1 Proteasome Fluorogenic Assay for Determination of IC50’s..................... 109 
4.4.2 High Through-put Screening for Novel Proteasome Inhibitors ................ 110 
4.4.3 In vitro Binding Assay .............................................................................. 112 
4.4.4 Cell Based Binding Assay ......................................................................... 114 
4.4.5 Cell Based Toxicity Assays ....................................................................... 116 
5. DUAL PROTEASOME/FATTY ACID SYNTHASE INHIBITORS ....................... 117 
5.1 Introduction ...................................................................................................... 117 
5.2 Results and Discussion ..................................................................................... 124 
5.3 Conclusions ...................................................................................................... 129 
5.4 Materials and Methods ..................................................................................... 130 
6. CONCLUSIONS ........................................................................................................ 132 







LIST OF FIGURES 
Page 
Figure 1 Ubiquitin proteasome pathway. Adenylation of ubiquitin by an E1 enzyme 
is followed by its transfer to an E2 ubiquitin-conjugating enzyme. An E3 
ligase covalently attaches ubiquitin to a lysine residue in the target protein. 
The ubiquitin chain is extended by E3, and substrates with at least five 
ubiquitin molecules are degraded by the 26S proteasome. Adapted from 
[17] ...................................................................................................................... 5 
Figure 2 Comparison of proteasome core particles from archaea ( T. acidophilum), 
eukaryotes (S. cerevisiae), and vertebrates (M. musculus). Structures are 
depicted in surface representation. The α-subunits are shown in red, 
catalytic β-subunits in purple, and non-catalytic β-subunits are blue. All     
β-subunits of T. acidophilum are catalytic, whereas six of the fourteen β-
subunits from eukaryotes and vertebrates are catalytic, with three distinct 
cleavage specificities; chymotrypsin-like, trypsin-like, and caspase-like. ......... 8 
Figure 3 Proteasome core particle isoforms. Inactive subunits are colored grey. 
Caspase-like sites (1) are colored green; Trypsin-like sites (2) are   
colored orange; Chymotrypsin-like sites are colored red for the cCP and 
iCP, and blue for the tCP. ................................................................................. 10 
Figure 4 Peptide bond hydrolysis by the proteasome. The nucleophilic Thr1Oγ (red) 
attacks the electrophilic carbonyl carbon atom of the peptide bond thereby 
releasing the first cleavage product. In a second step, hydrolysis of the 
formed acyl-enzyme complex (green bond) frees the N-terminal cleavage 
product and restores the catalytic Thr1. (Adapted from [16]) .......................... 13 
Figure 5 Schematic representation of the proteasomal substrate binding channel of 
the proteasomal active sites. The primed (S’) pockets and the P’ sites of the 
ligand are colored in blue, and the unprimed specificity (S) pockets and the 
corresponding substrate residues (P) are colored green. The active site, 
including Thr1 and the scissile peptide bond are shown in red. (Adapted 
from [16]) .......................................................................................................... 14 
Figure 6 Chemical structures of clinically relevant proteasome inhibitors. Bortezomib 
and carfilzomib are FDA approved for the treatment of multiple myeloma 
and refractory multiple myeloma, respectively. Oprozomib is in clinical 
trials for treatment of multiple myeloma as well as solid tumors. .................... 22 
 ix 
 
Figure 7 Chemical structures of subunit specific proteasome inhibitors. PR-957 
targets immunoproteasome subunit 5i; PI-1840 targets constitutive 
proteasome subunit; 5c; NC-022 specifically targets trypsin-like subunits 
of immuno and constitutive proteasomes (2c/2i). ........................................ 24 
Figure 8 Sequence alignments of proteasomes caspase-like (1) constitutive (c) and 
immuno (i) subunits from Homo sapien (hu), Mus musculus (mu), and T. 
acidophilum (y). Secondary structures (S: -sheet; H: helix) are indicated 
for the human constitutive subunits. Residues important for the active site 
are indicated with red boxes. Residues contributing to the substrate-
specificity pockets are highlighted by colored boxes: S1 pocket, green; S2 
pocket, blue; S3 pocket, yellow. ....................................................................... 33 
Figure 9 Sequence alignments of proteasomes trypsin-like (2) constitutive (c) and 
immuno (i) subunits from Homo sapien (hu), Mus musculus (mu), and T. 
acidophilum (y). Secondary structures (S: -sheet; H: helix) are indicated 
for the human constitutive subunits. Residues important for the active site 
are indicated with red boxes. Residues contributing to the substrate-
specificity pockets are highlighted by colored boxes: S1 pocket, green; S2 
pocket, blue; S3 pocket, yellow. ....................................................................... 34 
Figure 10 Sequence alignments of proteasomes chymotrypsin-like (5) constitutive 
(c) and immuno (i) subunits from Homo sapien (hu), Mus musculus (mu), 
and T. acidophilum (y). Secondary structures (S: -sheet; H: helix) are 
indicated for the human constitutive subunits. Residues important for the 
active site are indicated with red boxes. Residues contributing to the 
substrate-specificity pockets are highlighted by colored boxes: S1 pocket, 
green; S2 pocket, blue; S3 pocket, yellow. ....................................................... 35 
Figure 11 One-dimensional SDS-PAGE analysis of purified human proteasome 
constitutive core particles ................................................................................. 38 
Figure 12 Proteasome crystal and diffraction from condition containing Peg 8K, 
sodium chloride, and cesium. ........................................................................... 39 
Figure 13 Proteasome crystals and diffraction from condition containing 40% MPD 
and 0.2M Sodium Formate. .............................................................................. 39 
Figure 14 Ramachandran Plot for human 20S proteasome crystal structure. .................. 41 
Figure 15 Quaternary structure of α-subunits. Subunit α5 is shown in ribbon 
representation, with each α-helix labeled as H, and β-sheets are labeled      
as S. ................................................................................................................... 45 
 x 
 
Figure 16 Quaternary structure of β-subunits. All -type subunits have a similar 
arrangement of two -helices, H1 and H2, followed by two sets of five-
stranded anti-parallel -sheets, then two more -helices, H3 and H4. An 
additional two-stranded -sheet is found in the loop connecting -strands  
S2 and S5. Subunit 5 (shown) has an additional two-turn -helix at its     
C-terminal end. ................................................................................................. 45 
Figure 17 Conserved C-terminal loop of 2 subunits. The C-terminus of subunit 2, 
from residue Leu186 to Glu220, wraps around subunit 3 and forms an 
additional strand in its anti-parallel -sheet, S12. The black arrow indicates 
the C-terminus of 2. ........................................................................................ 47 
Figure 18 Surface representation of the human 20 proteasome. Subunits are colored 
according to their symmetrical counterpart. ..................................................... 48 
Figure 19 Ribbon representation of top view of the α-subunits. The arrows indicates 
the entry to the catalytic chamber, which is closed off by the N-termini of 
the -subunits. The 20S core can be activated by proteins such as the 19S 
regulatory particle, which inserts short C-terminal peptide segments into 
shallow pockets on the -ring surface, causing structural rearrangements. 
Each -subunit is colored uniquely. ................................................................. 48 
Figure 20 Structural alignment of proteasome catalytic subunits. Human (wheat), 
yeast (yellow) and mouse (teal). ....................................................................... 49 
Figure 21 Active site of catalytic subunits β1, β2, and β5. Residues involved in 
catalysis are shown in magenta, and are conserved in all three distinct 
catalytic subunits. Hydrogen bonds are shown as black dashed lines, and  
the unique network increases the nucleophilicity of Thr1. Thr1 is shown in 
black, and the active site water, WAT, is shown as a yellow sphere. The 
water may be involved in intramolecular autolysis and substrate   
proteolysis by mediating proton transfer between Thr1O and Thr1N. ........... 51 
Figure 22 S1 specificity pockets of the catalytic β-subunits. ........................................... 53 
Figure 23 Proteasome reaction mechanism against epoxyketone inhibitors.  The 
carbonyl carbon atom is attacked by the proteasomes Thr1O nucleophile. 
The formed hemiketal intermediate can either dissociate to deliberate 
Thr1Oγ or irreversibly cycle under the formation of a secondary amine 
(morpholine ring system) involving Thr1N. ..................................................... 59 
Figure 24 View of the inner cavity of the human 20S proteasome with carfilzomib 
bound. The 4 and 4-subunits have been removed to give a view of the 
 xi 
 
core of the 20S proteasome. Carfilzomib, shown as green sticks, is bound  
to all six active sites. ......................................................................................... 63 
Figure 25 Ramachandran plot for carfilzomib bound human 20S proteasome. ............... 64 
Figure 26 Surface representation and electron density of carfilzomib bound to the 
chymotrypsin-like active site. Thr1 is colored black; carfilzomib is colored 
green; electron density is blue and is contoured to 1. .................................... 65 
Figure 27 Carfilzomib bound to the trypsin-like subunit, 2. .......................................... 66 
Figure 28 Carfilzomib bound to caspase-like site, 1. ..................................................... 66 
Figure 29 Hydrogen bonding interactions of carfilzomib in the chymotrypsin like 
subunit β5. Hydrogen bonds are indicated with black dashed lines; the 
active site water molecules are shown as red spheres. The nucleophilic  
Thr1 is shown in black. ..................................................................................... 67 
Figure 30 Hydrogen bonding interactions of carfilzomib in the trypsin-like subunit 
β2. Hydrogen bonds are indicated with black dashed lines; the active site 
water molecules are shown as red spheres. The nucleophilic Thr1 is shown 
in black. ............................................................................................................. 68 
Figure 31 Hydrogen bonding interactions of carfilzomib in the caspase-like subunit 
β1. Hydrogen bonds are indicated with black dashed lines; the active site 
water molecules are shown as red spheres. The nucleophilic Thr1 is shown 
in black. ............................................................................................................. 68 
Figure 32 Structural alignment of chymotrypsin-like and caspase-like sites with 
carfilzomib bound. In caspase-like sites, H116 prevents carfilzomibs P4 
phenyl group from accessing the S4 pocket (black arrow), resulting in a 
disordered N-terminus of the drug and decreased selectivity. The N-
terminal morpholino ring in chymotrypsin-like sites assumes a fixed 
conformation due to steric effects of Y107. ..................................................... 69 
Figure 33 Structural alignment of the chymotrypsin-like sites of the 
human:carfilzomib, yeast:bortezomib, and mouse:PR-957 complexes.     
The black arrow indicates the P2 residue, which is flipped in carfilzomib 
(green) and PR-957(white) relative to the P2 phenylalanine of bortezomib 
(pink). Thr1 is shown in black, and the specificity pockets which harbor 
ligand side chains are labeled as S1-S4. ........................................................... 71 
Figure 34 Shifts in the S1 pocket of the human proteasome chymotrypsin-like 
subunit, 5, upon carfilzomib binding. Unbound and carfilzomib bound 
structures are aligned by their C atoms. The unbound 5 is colored white, 
 xii 
 
carfilzomib bound 5 is wheat, carfilzomib is colored green, and Thr1 is 
black. Regions of the protein that shift upon carfilzomib binding are 
indicated with black arrows. ............................................................................. 73 
Figure 35 PR-957 bound to mouse constitutive 20S Proteasome chymotrypsin-like 
site. The same structural rearrangements are observed as in the 
carfilzomib:proteasome structure, indicated with black arrow.  The   
unbound protein is teal, PR-957 bound is Pink, and PR-957 is yellow   
(PDB ID unbound, 3UNE; PR-957 bound, 3UNB). ......................................... 74 
Figure 36 PR-957 bound to mouse 20S immunoproteasome chymotrypsin-like site. 
Same color scheme as figure 36. No structural rearrangements are   
observed due to Gln53 stabilizing Met45 resulting in a larger S1 pocket 
than constitutive proteasomes β5 (PDB ID unbound, 3UNH; PR-957  
bound, 3UNF). .................................................................................................. 75 
Figure 37 Carfilzomibs P3 and P4 residues contribute to its increased selectivity for 
constitutive proteasomes chymotrypsin-like sites compared to PR-957. 
Carfilzomib (left image) has a P3 leucyl group and P4 phenyl group which 
stabilize ligand binding. PR-957 (right image) has a smaller alanine at P3 
and no P4 residue, resulting in decreased selectivity towards constitutive 
proteasomes chymotrypsin-like sites and more favorable binding to 
immunoproteasomes. ........................................................................................ 76 
Figure 38 Structural alignment of the chymotrypsin-like subunit β5c of the human 
proteasome:carfilzomib complex with the corresponding mouse immuno 
subunit β5i.  The human proteasome subunit is shown in wheat; carfilzomib 
is shown in green; the active site Thr1 from human is shown in black; 
mouse immuno subunit is shown in white. Conserved amino acid 
substitutions are shown as white sticks and labeled in black. Residue 
substitutions not conserved with human β1i are shown as black sticks, with 
the human substitution shown in black in parenthesis. Red labels are of the 
constitutive particle residue that is substituted. ................................................ 80 
Figure 39 Structural alignment of the trypsin-like subunit β2c of the human 
proteasome:carfilzomib complex with the corresponding mouse immuno 
subunit β2i. The same color scheme is used as Figure 40. ............................... 81 
Figure 40 Structural alignment of the human caspase-like subunit β1c with the 
corresponding mouse immuno subunit β1i. The same color scheme is used 
as Figure 40-41. ................................................................................................ 82 
Figure 41 Chemical structure of -mangostin ................................................................. 92 
 xiii 
 
Figure 42 In vitro inhibition of chymotrypsin-like and caspase-like activities of the 
proteasome by -mangostin. The IC50 values against the chymotrypsin-like 
and caspase-like activities were calculated to be 700 nM, and 1.5 M, 
respectively. Error bars represent standard deviations of triplicate 
experiments. ...................................................................................................... 93 
Figure 43 In vitro binding assay of -mangostin against human 20S proteasome.  
Lane 1 contains only proteasome and probe; lane 2 shows bortezomib as a 
positive control for probe binding; lane 3 is -mangostin. The diminished 
band intensities signify binding of inhibitor to the catalytic site indicated. ..... 94 
Figure 44 IC50 Graph against Molt4 Leukemia Cells IC50 value is approximately 
15µM. ............................................................................................................... 95 
Figure 45 IC50 Graph against human dermal fibroblasts .................................................. 96 
Figure 46 Western Blot Analysis of α-Mangostin in Molt4 Leukemia Cells. ................. 97 
Figure 47 In vitro binding assay of purified human 20S proteasome. Lane 1 is a 
control with no inhibitor, only probe. Lane 2 had proteasome incubated  
with bortezomib prior to addition of probe. Lane 3 was proteasome 
incubated with PPH-1 prior to addition of probe. The diminished band 
intensities compared to lane 1 indicates binding of the inhibitors. ................... 99 
Figure 48 Chemical structure of PPH-1 ........................................................................... 99 
Figure 49 In vitro enzymatic activity of PPH-1 against chymotrypsin-like activity. 
The IC50 against chymotrypsin-like site was determined to be 15 µM. ......... 100 
Figure 50 In vitro enzymatic activity PPH-1 against caspase-like sites. The IC50 
against caspase-like sites was determined to be 15 µM. ................................ 100 
Figure 51 Activity of PPH-1 against cancer cell lines. Cell lines tested were    
OVCAR 3(ovarian cancer), MDA-MB-231(breast cancer), and multiple 
myeloma cell lines 2631, and G3. .................................................................. 102 
Figure 52 Binding Assay for hit plate screen hits. Bortezomib (BTZ) was used as a 
positive control for inhibitor binding. None of the hits from the screen  
show diminished band intensity compared to the “no inhibitor” control, 
therefore they were not further pursued as possible proteasome inhibitors. .. 106 
Figure 53 Structures of natural product polyphenol proteasome inhibitors. .................. 108 
Figure 54 Proteasome binding probe. (Left) Schematic of the probe. (Right) Probe. ... 114 
 xiv 
 
Figure 55 Proteasome and Fatty Acid Synthase Inhibitors. Orlistat (bottom right) 
inhibits fatty acid synthase, the remaining compounds inhibit the 20S 
Proteaome. ...................................................................................................... 121 
Figure 56 Design of dual proteasome/fatty acid synthase inhibitors from orlistat and 




LIST OF TABLES 
 Page 
 
Table 1 Chemical Structures of Proteasome Inhibitors .................................................... 19 
Table 2 Crystallography Statistics .................................................................................... 42 
Table 3 High Through-Put Screening Hits from Hit Plate ............................................. 103 
Table 4 First Generation of Dual Proteasome/FAS Inhibitors ....................................... 123 






1. INTRODUCTION  
 
1.1 Protein Degradation 
  
Proteases perform many tasks vital to the cell. As cellular structures are continually 
rebuilt, homeostasis between anabolic and catabolic pathways must be maintained [1]. 
Mis-folded and malfunctioning proteins, prone to aggregation, must be scavenged and 
degraded. Otherwise, these abnormal proteins would accumulate in the cell, endangering 
the cell’s functionality. In addition, the activity of many regulatory proteins is also 
controlled by means of their degradation. Proteases vary from small proteins such as 
extracellular trypsin and the intracellular caspases, to large ATP-dependent 
multifunctional proteases called proteasomes.  
 Lysosomes are specialized membrane-enclosed organelles that contain an array of 
digestive enzymes. Until the early 1980’s lysosomes were believed to be the site of all 
protein degradation. It is now known that the role of lysosomes is limited to metabolism, 
including the digestion of extracellular proteins taken up by endocytosis as well as the 
gradual turnover of cytoplasmic organelles and cytosolic proteins [2]. In lysosomes, 
proteases termed cathepsins unselectively degrade proteins. The resulting peptide 
fragments can be loaded on major histocompatibility complex class (MHC) II receptors 
and presented on the cell surface to immune cells [3].  
 The task of breaking down damaged, misfolded, or no longer needed proteins, 
however, is performed by the 26S proteasome.  In the cytoplasm and in the nucleus of 
 2 
eukaryotic cells, the ubiquitin/proteasome system (UPS) provides the main mechanism for 
a selective and ATP-dependent degradation of short-lived proteins. Proteasome 
degradation is responsible not only for removal of damaged protein in quality control, but 
also for precise regulation of the cell cycle [4], transcription [5], and antigen presentation 
[6]. The 26S proteasome is composed of a multi-subunit 20S core particle (20S 
proteasome) and two multi-subunit ATP dependent regulatory particles (19S regulatory 
complex), which selectively cuts polyubiquitinated proteins to peptides of diverse 
lengths[7].  
 In the ubiquitin/proteasome system, proteins to be degraded are covalently 
modified at a lysine residue by a string of ubiquitin molecules, yielding a 
polyubiquitinated form of the protein which as a substrate for proteasome degradation. 
This modification leads to the identification of the tagged protein by the 19S regulatory 
particle of the proteasome, which then unfolds the protein and feeds it into the 20S core 
particle where proteolysis takes place.  
A number of proteins that control fundamental cellular processes, such as gene 
expression and cell proliferation, are targets for regulated ubiquitination and proteolysis 
[8]. An example is the controlled degradation of cyclins, which regulate progression 
through mitosis in eukaryotic cells.  The entry of all eukaryotic cells into mitosis is 
controlled in part by cyclin B, which is a regulatory subunit of a protein 
kinase called Cdc2. The association of cyclin B with Cdc2 is required for activation of the 
Cdc2 kinase, which initiates the events of mitosis (including chromosome condensation 
and nuclear envelope breakdown) by phosphorylating various cellular proteins [9]. Cdc2 
 3 
also activates a ubiquitin-mediated proteolysis system that degrades cyclin B toward the 
end of mitosis [10]. This degradation of cyclin B inactivates Cdc2, allowing the cell to 
exit mitosis and progress to interphase of the next cell cycle. The ubiquitination of cyclin 
B is a highly selective reaction, targeted by a 9-amino-acid cyclin B sequence called the 
destruction box [11]. Mutations of this sequence prevent cyclin B proteolysis and lead to 
the arrest of dividing cells in mitosis, demonstrating the importance of regulated protein 
degradation in controlling the fundamental process of cell division.  
  Additionally, many of the peptides produced by proteasome degradation are 
further broken down to single amino acids; however, in vertebrates a fraction goes on to 
serve as antigens for the immune system.  The peptides transit to the lumen of the 
endoplasmic reticulum (ER)  by the transporter associated with antigen processing (TAP), 
a member of the ATP-binding cassette transporter family[12]. Once in the ER, peptides 
can associate with the binding cleft of nascent MHC I receptors based on affinity for the 
MHC I complex, which is dependent on the peptides C-terminal anchor [13]. Cleavage 
preferences of the proteasome dictate the C-terminal anchors, and once peptides are bound 
to the MHC I complex, only stable receptor:ligand complexes adopt a mature structure 
and are transported in vesicles to the cell membrane for their exposure to the extracellular 
environment. Cytotoxic T lymphocytes destroy bacterial or viral peptides which are 
identified by surveying effector cells of the immune system that monitor the peptide 
cargos of both MHC I and II receptor proteins [14].  Therefore, the proteasome plays a 
key role in the immune system by shaping the antigenic pool of peptides. 
 
 4 
1.2 Ubiquitin Proteasome System  
  
 The field of ubiquitin and regulated protein degradation was created in the 1980’s, 
largely through the complementary discoveries by the laboratories of A Hershko 
(Technion, Haifa, Israel) and A Varshavsky (MIT, Cambridge, MA) [3].  Hershko and his 
colleagues revealed the initial understandings of ubiquitin conjugation and ubiquitin-
mediated proteolysis in cell extracts, while Varshavsky and colleagues uncovered the 
specific biological necessity of the ubiquitin proteasome system in the cell cycle, DNA 
repair, protein synthesis, transcriptional regulation, and stress response. These discoveries 
caused a major expansion of the ubiquitin field in the 1990’s, and it became clear that 
control through regulated protein degradation rivals, and may even surpass in significance, 
the classical regulation through transcription and translation.  
 Defective or outlived intracellular proteins undergo posttranslational modification 
via ubiquitination, thereby rendering them targets for degradation by the 26S proteasome.  
Ubiquitin is a 76-residue polypeptide and is covalently linked to the target protein through 
the formation of an isopeptide bond between the amino group of a substrate’s lysine 
residue, and ubiquitin’s C terminus. This reaction process involves three separate 
enzymes: E1, an ATP dependent activating enzyme which forms a thiol ester with the 
carboxyl group of ubiquitins C-terminal G76 residue, rendering it ready for nucleophilic 
attack of a substrates lysine side chain; E2, a conjugating enzyme responsible for carrying 
the activated ubiquitin molecule to ligase E3; and E3, which is bound specifically to the 
substrate, and facilitates the attachment of the  ubiquitin molecule to the substrate lysine, 
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as well as the attachment of additional ubiquitins to form a chain [15] (Figure 1).  Several 
classes of E3 enzymes exist, lending to selectivity due to their ability to bind to recognition 
sites in their target proteins. Recognition of ubiquitin tagged proteins by the 26S 
Proteasome requires a chain of at least four ubiquitin molecules, whereas proteins tagged 





Figure 1 Ubiquitin proteasome pathway. Adenylation of ubiquitin by an E1 enzyme is 
followed by its transfer to an E2 ubiquitin-conjugating enzyme. An E3 ligase covalently 
attaches ubiquitin to a lysine residue in the target protein. The ubiquitin chain is 
extended by E3, and substrates with at least five ubiquitin molecules are degraded by the 




1.3 Proteasomes Assembly and Architecture  
  
 Cellular homeostasis is maintained by the proper recognition, unfolding, 
translocation and cleavage of protein substrates. The success of the proteasome is 
dependent on proper assembly and regulation of the approximately 2.5 MDa complex, 
formed by the 28 subunit core particle (CP), or 20S proteasome, and two 19S regulatory 
particles (RP) which cap each end. The entire complex is termed the 26S proteasome, and 
each subunit plays an important role in ensuring proper protein function. The importance 
of the eukaryotic proteasome is exemplified by its early evolutionary origin, with 
homologous proteins found in archaeon’s, and eubacteria. Proteasome CP’s have been 
extensively studied and the following summarizes the current understandings of its 
evolution and function.  
 Bacteria, with the exception of actinomycetes, harbor a protease termed heat shock 
locus V (Hs1V), composed of two hexameric rings, with each subunit having peptide 
cleavage activity through an N-terminal threonine residue [18].  In contrast, the crystal 
structure of the 20S proteasome from archaeon Thermoplasma acidophilum revealed a 
hollow cylinder shape, comprised of four stacked rings of seven subunits each, with an 
overall cylinder length of 148 Å.  The approximately 700 kDa protein has two types of 
subunits present, termed  and , which are arranged as 7777. With the exception of 
Aeropyrum pernix, all  subunits of archaebacterial proteasomes are catalytically active 
and share homology with the subunits from Hs1V proteases, and all act through N-
terminal threonine residues [19].  
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 In contrast to the low subunit complexity of prokaryotic proteasomes, eukaryotic 
proteasomes CPs are composed of 14 distinct subunits; seven  type and seven  type. 
Crystal structures of proteasome CP’s from Saccharomyces cerevisiae, Bos taurus and 
Mus musculus, show that the CP’s have a subunit arrangement similar to that of T. 
acidophilum, only they possess C2 symmetry rather than sevenfold symmetry [20](Figure 
2).  Furthermore, only subunits 1, 2, and 5 have been shown to harbor catalytic activity 
through N-terminal Thr1 residues.  
 The α subunits are also attributed with several functions. Their intrinsic ability to 
form a heptameric ring is pivotal for the assembly of the β subunits and the formation of 
the CP. Additionally, “shuttling sequences” in the α subunits enable the import of the CP 
into the nucleus and its re-export. The α subunits also form the entry gate to the interior of 
the CP. Specifically, the N-terminal extensions of the subunits α2, α3, and α4 close the CP 




Figure 2 Comparison of proteasome core particles from archaea ( T. acidophilum), 
eukaryotes (S. cerevisiae), and vertebrates (M. musculus). Structures are depicted in 
surface representation. The α-subunits are shown in red, catalytic β-subunits in purple, 
and non-catalytic β-subunits are blue. All β-subunits of T. acidophilum are catalytic, 
whereas six of the fourteen β-subunits from eukaryotes and vertebrates are catalytic, 
with three distinct cleavage specificities; chymotrypsin-like, trypsin-like, and caspase-
like.  
  
 Construction of the core particle begins with the  rings. Four CP-chaperones, Pba 
(proteasome biogenesis associated protein) in yeast, and PAC (proteasome assembly 
chaperone) in human, are responsible for the assembly process. The chaperones are 
functional as heterodimers, PAC1-PAC2 and PAC3-PAC4. Upon completion of -ring 
assembly the  subunits are incorporated and PAC3-PAC4 is released due to steric 
hindrance with 4. A fifth chaperone, Ump1/POMP, acts to ensure that the two half CP’s 
do not dimerize until all seven  subunits have been assembled.  
 Five of the seven -type subunits, including the three catalytic subunits (1, 2, 
and 5) are synthesized as proproteins, which are proteolytically processed to their mature 
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forms found in the assembled core particle [21].  These propeptides are involved in CP 
assembly assisted by the proteasome maturation factor Ump1 and protect the catalytic 
active sites from inactivating Nα acetylation prior to proteasome maturation [22]. Upon 
completion of CP assembly the propeptides are removed by intramolecular autolysis, 
exposing the proteolytically active Thr1 residues and leaving the proteome ready to cleave 
polypeptides that are fed into the 20S core, beginning with the degradation of Ump1 and 
PAC1-PAC2 [23, 24].  
 All seven distinct  and  subunits have the same general -sandwich architecture, 
which is typical for N-terminal hydrolases [25].  The -sandwich consist of three  helices 
H1, H2 and H3, followed by two five-stranded antiparallel  sheets, then three additional 
 helices, H4, H5 and H6 on the opposite side of the β sheets.  
  Proteins that activate the 20S core for proteolysis, such as the 19S RP, the 11S 
regulator, and  proteasome-activating nucleotidase (PAN), insert C-terminal peptide 
segments of ~6 residues into shallow pockets on the -ring surface [26]. ATPase 
regulatory particles contain a C-terminal hydrophobic-tyrosine-X (HbYX motif), which 
has been shown to be crucial for activation of the 20S core. Interaction of the HbYX motif 
with the proteasome -chains, results in substantial structural rearrangements which allow 
access to the interior cavity [27].   
Hydrophobic molecules such as rapamycin, have been shown to prevent binding 
of the 19S RP, thereby acting as allosteric inhibitors of the proteasome [28]. Additionally, 
prion proteins, which form aggregated -sheet isoforms, inhibit proteasome activity by 
stabilizing the entry gate and preventing its opening [29].  
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Figure 3 Proteasome core particle isoforms. Inactive subunits are colored grey. 
Caspase-like sites (1) are colored green; Trypsin-like sites (2) are colored orange; 
Chymotrypsin-like sites are colored red for the cCP and iCP, and blue for the tCP.  
  
 Unlike yeast and other primitive eukaryotes, vertebrates encode for three types of 
core particles: constitutive proteasome (cCP), immunoproteasome (iCP) and the 
thymoproteasome (tCP) [30] (Figure 3). The constitutive core particle comprises the 
catalytic active constitutive subunits β1c, β2c, and β5c, and represents the prevailing 
proteasome species in cells of non-hematopoietic origin. The immunoproteasome, iCP, is 
expressed predominantly in immune tissues and cells such as monocytes and lymphocytes 
[21]. The expression of the iCP catalytic subunits, 1i/LMP2, 2i/MECL-1, and 
5i/LMP7, can also be induced by tumor necrosis factor- and interferon-, which are 
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released by T cells during infection [31]. These immunoproteasome subunits replace their 
constitutive counterparts, and preferentially hydrolyze proteins after nonpolar amino acids 
[32]. This results in peptide fragments having hydrophobic C termini, which then anchor 
to MHC-1 molecules, thus priming the immune system.  It has been shown in gene-
targeted mice, however, that immunoproteasome subunits are not required for epitope 
presentation [33], therefore constitutive CPs must also be capable of antigen processing. 
Interestingly, mixed proteasomes of the composition β1c, β2c, and β5i or β1c, β2i, and 
β5i were reported to account for 30-50% of all cellular CPs, which further broadens the 
repertoire of antigens presented to CD8 T cells, and suggests that the antigens presented 
by a given cell depends on their proteasome content [34].  
 The third type of CP, thymoproteasome (tCP) is specific to vertebrate and is 
exclusively expressed in cortical thymic epithelial cells. The subunit arrangement in tCP 
only replaces β5i with β5t (PSMB11), while the remaining catalytic subunits remain that 
of the immunoproteasome, β1i and β2i. This tCP has been implicated to play a pivotal role 
for the development of CD8+ cytotoxic T cells as part of the adaptive immune system 
[35].  
  
1.4 Proteasome Proteolysis   
  
 The proteasome is a threonine protease and belongs to the family of N-terminal 
nucleophile hydrolases. Six of the proteasomes β-chains contain catalytic N-terminal Thr1 
residues, however there are three distinct cleavage specificities: trypsin-like (T-L, chains 
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2/β2’), chymotrypsin-like (CT-L, chains 5/5’) and caspase-like (C-L, chains 1/1’). 
Trypsin-like subunits cleave after basic residues such as lysine or arginine, caspase-like 
sites cleave after acidic residues, and chymotrypsin-like sites cleave after hydrophobic 
residues.  
Despite varying substrate selectivity’s, the catalytic mechanism is the same for all 
three active sites (Figure 4). Thr1O is activated by a conserved water molecule and 
nucleophilically attacks the substrates electrophilic carbonyl carbon atom of the peptide 
bond [36]. A tetrahedral intermediate is formed, which collapses to release one substrate 
degradation product. Hydrolysis of the formed acyl-enzyme complex frees the N-terminal 
cleavage product and restores the catalytic Thr1.   
 The binding affinity of a substrate for its target is dictated by both entropic and 
enthalpic contributions, according to Gibbs energy of binding (G), Ka = 𝑒
𝐺
𝑅𝑇. Several 
studies using peptide-based inhibitors have shown that it is enthalpic interactions with the 
proteasomes’ primed (S1’, S2’, S3’) and unprimed (S1, S2, S3) substrate-binding pockets 
that drive the affinity of a substrate toward a particular active site [37, 38]. The binding 
pockets (S) accommodate the side chains of substrates, or P residues (Figure 5). The active 
site preferences (chymotrypsin-like, trypsin-like, or caspase-like) correspond to the 
interactions of the side chain of the last residue before the cleavage site, P1, with the S1 
pocket. In particular, amino acid 45 at the base of the S1 pocket is believed to dictate the 
active sites substrate selectivity [39].     
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Figure 4 Peptide bond hydrolysis by the proteasome. The nucleophilic Thr1Oγ (red) 
attacks the electrophilic carbonyl carbon atom of the peptide bond thereby releasing the 
first cleavage product. In a second step, hydrolysis of the formed acyl-enzyme complex 
(green bond) frees the N-terminal cleavage product and restores the catalytic Thr1. 
(Adapted from [16]) 
14 
Figure 5 Schematic representation of the proteasomal substrate binding channel of 
the proteasomal active sites. The primed (S’) pockets and the P’ sites of the ligand are 
colored in blue, and the unprimed specificity (S) pockets and the corresponding substrate 
residues (P) are colored green. The active site, including Thr1 and the scissile peptide 
bond are shown in red. (Adapted from [16])  
1.5 Immune Functions of the Proteasome 
The evolution of the immune system in higher vertebrates brought with it a new 
role for the proteasome and lysosome in facilitating the immune system by screening 
foreign material in the extracellular and intracellular spaces [40]. Lysosomes are tasked 
with degrading extracellular proteins that are taken in by endocytosis, which produces 
antigenic peptides that are presented on MHC class II molecules and elicit antibody 
production. 
Proteasomes, on the other hand, shape the pool of antigenic peptides that are 
presented by MHC I receptors on the cell surface to immune cells. All three proteasome 
types, cCP, iCP, and tCP, are capable of degrading intracellular proteins and generating 
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antigens. To bind to most MHC class I molecules, peptides have to be eight to nine 
residues long and have to have hydrophobic or basic C-termini. While a majority of the 
peptides generated are hydrolyzed by cytosolic peptidases to amino acids within a matter 
of seconds, a small fraction, approximately 30%, escape hydrolysis and are transported by 
the TAP transporter into the ER. Peptides that are longer than eight or nine residues are 
further trimmed by the aminopeptidase, ERAP1, and then all bind to MHC class I 
molecules and are delivered to the cell surface for presentation to circulating lymphocytes.   
 Although cCP peptides can trigger immune reaction, the iCP is the preferred form 
due to its ability to a higher fraction of peptides with the appropriate C-terminal anchor. 
During viral infection, cytokines are released which induce the expression of iCP’s therby 
enhancing antigen presentation and supporting the clearing of pathogens [33].  
 The tCP is restricted to the cortical thymic epethial cells (cTECs) of the thymus, 
and this specialized organ of the immune system selects T lymphocytes for the optimal 
interaction strength of their T cell receptor (TCR) with MHC:self-peptide complexes. 
Interactions between the TCR and MHC can either be tight or weak, resulting in either 
negative or positive selection, respectively. Immature thymocytes whose TCR tightly 
binds to MHC receptors loaded with self-antigens are auto-reactive and are eliminated by 
negative selection, while T cells with weak TCR:MHC interactions are considered as self-
tolerant and thus survive, positive selection[21, 41]. Chymotrypsin like activity is 
decreased in tCPs and this is believed to produce low-affinity self-epitopes for the 
presentation on MHC receptors, supporting positive selection [42]. To summarize, the tCP 
helps to establish a tolerant T cell repertoire, the prerequisite for a functional adaptive 
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immune system and the iCP and cCP promote immune surveillance and the elimination of 
pathogens. Therefore, all three are key players of the adaptive immune system in 
vertebrates and their malfunctioning positively correlates with the onset of diverse 
diseases.  
 
1.6 20S Proteasome: Inhibition and Apoptosis  
 
 The 20S proteasome primarily serves to degrade regulatory or aberrant proteins 
[43], including: oncoproteins [44], transcription factors [45], cell cycle specific cyclins 
[4], cyclin-dependent kinase inhibitors [46], ornithine decarboxylase [47], and other key 
regulatory cellular proteins. Altered regulation of these events is linked to the development 
of cancers as well as autoimmune disorders [48], and thus the proteasome has become an 
attractive target for the treatment of such diseases.  
 Due to accelerated cell cycles and metabolism in tumour cells, the CP is often 
upregulated to increase turnover rates of proteins. This dependence on CP activity renders 
neoplastic cells highly susceptible to proteasome inhibition. Early studies established that 
proteasome inhibitors induce apoptosis in leukemic cell lines [49, 50], and additional in 
vitro studies revealed anti-proliferative and pro-apoptotic activity against hematological 
and solid tumors. Multiple myeloma cells have been found to be the most sensitive to CP 
inhibitors [51]. Myeloma cells are derived from plasma cells and their excessive synthesis 
of immunoglobulins as well as their chromosomal instability leads to many aberrant and 
misfolded proteins that have to be removed by the proteasome. Proteasome inhibitors 
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mainly induce apoptosis in proliferating cells and are protective against quiescent or 
terminally differentiated cells [50]. Inhibition of the proteasome causes the accumulation 
of protein aggregates and triggers ER stress as well as the unfolded protein response [52].  
 The exact mechanisms behind the higher sensitivity of malignant cells for 
proteasome inhibitors is unclear, however, induction of apoptosis can occur through a 
variety of pathways depending on the cell type. For instance, in MOLT-4 human T cell 
leukemia, proteasome inhibition leads to an increase in the tumor suppressor p53, which 
initiates genes that induce cell growth arrest, DNA repair or apoptosis [53]. In multiple 
myeloma and mantle cell lymphoma cell lines, proteasome inhibition prevents degradation 
of the inhibitor of the transcription factor NFB (IBα), blocking the expression of anti-
apoptotic target genes [54-56].  This causes the induction of apoptosis in transformed cells 
by tumor suppressor genes such as cyclin kinase inhibitor p27kip1 [57], however, healthy 
cells remain unaffected [51], resulting in a therapeutic window for proteasome inhibition 
in hematological cancers.  
 
1.7 Classes of Proteasome Inhibitors  
  
 Proteasome inhibitors can be broadly broken down into either covalent or 
noncovalent inhibitors. Covalent inhibitors harbor an electrophilic head group that 
reversibly or irreversibly inhibits the catalytic Thr1Oλ. These can be further broken down 
into several more specific categories based on the type of pharmacophore: aldehydes, 
vinyl sulfones, vinyl amides (syrbactins), bornic acids, α’,β’epoxyketones, α 
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ketoaldehydes (glyoxals) and β lactones.  With the exception of lactones and syrbactins, 
proteasome inhibitors consist of a peptide backbone of two to four amino acids attached 
to the electrophilic head group (Table 1). The crystal structure of the yeast proteasome in 
complex with calpain inhibitor I (acetyl-Leu-Leu-norleucinal) showed that the peptide 
backbone completes an antiparallel β-sheet in the substrate binding channel and the 
inhibitor side chains facilitate with active site selectivity by interacting with the 
proteasomes specificity pockets [21]. This has been consistent with other peptide based 
proteasome inhibitors to date, including PR-957 which was reported bound to the mouse 
immunoproteasome [16].  
 Peptide aldehydes inhibitors such as MG-132 (Z-Leu-Leu-Leu-H) are not suitable 
drug candidates because they are non-specific and block a broad range of serine and 
cysteine proteases. They are widely used, however, for in vitro and in vivo studies due to 
their cell permeability, and because their inhibition can be reversed [58].  Vinyl sulfones 
and naturally occurring syrbactins form an ether bond with Thr1Oλ in a Michael-type 1,4-
addition [59]. They are also non-specific and target cysteine proteases, limiting their use 
to in vivo and in vitro studies [60]. β lactones can be reversible or irreversible, depending 
on their P1 substituent [42], and marizomib ( salinosporamide A; NPI-0052; Nereus 
Pharmaceuticals, Inc.) is currently in clinical phase I trials for myeloma, lymphoma and 
leukemia [41].  
Boronic acids, such as bortezomib are among the most potent inhibitors of the 
proteasome and form a tetrahedral adduct with the active site Thr1O [36]. 
α’,β’epoxyketone inhibitors, such as epoxomicin, are also highly specific for the 
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proteasome. They irreversibly inhibit the proteasome in a bivalent reaction involving both 
Thr1Oγ and Thr1N [61]. α ketoaldehydes inhibit the proteasome by the formation of a 
reversible cyclic Schiff base with Thr1Oγ and Thr1N[51].  
 
 
Table 1 Chemical Structures of Proteasome Inhibitors 
  Chemical Name                 Structure 
 
 








Salinosporamide A (Marizomib) 
                     












1.8 Clinically Relevant Proteasome Inhibitors  
  
 The boronic acid proteasome inhibitor bortezomib (Velcade®, Millenium 
Pharmaceuticals, Inc.; PS-341) received FDA approval in 2003 for the treatment of 
multiple myeloma and relapsed or refractory mantle cell lymphoma [52]. The therapeutic 
benefit of using bortezomib during organ transplantation[62] and solid tumors such as 
non-small cell lung cancer is currently being investigated [63].  
Bortezomib potently inhibits the β5c, β5i and β1i active sites of the cCP and iCP 
with IC50 values of 3-8 nM, and targets the β1c, β2c and β2i subunits to a lesser extent 
[64]. Bortezomib inhibits via a single reversible covalent adduct with its reactive boronate 
and has moderate affinity for serine proteases, including cathepsin G, cathepsin A, 
chymase, dipeptidyl peptidase II and HtrA2/omi. HtrA2 is involved in neuronal survival 
Table 1 continued 
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[65], and inhibition by bortezomib is believed to be the cause of peripheral neuropathy in 
patients in about 30% of patients treated [65].  
 In 2012, carfilzomib (Kyprolis®, PR-171; Onyx Pharmaceuticals) was approved 
by the FDA for the treatment of refractory multiple myeloma. A twenty-eight day cycle 
of carfilzomib cost $10,000, making it the most expensive multiple myeloma drug on the 
market. Carfilzomib is the result of medicinal chemistry efforts to increase the potency 
and chymotrypsin like selectivity of the natural product proteasome inhibitor, epoxomicin. 
The bivalent, irreversible reaction mode of inhibition of α’,β’epoxyketones makes them 
the most specific proteasome inhibitors known [61]. Carfilzomib potently blocks the β5c 
and β5i active sites of cCPs and iCPs with IC50 values of 6 nM and 33 nM, respectively. 
Carfilzomib treatment has been linked to neutropenia and thrombocytopenia in patients, 
however, it does not cause peripheral neurotoxicity, as observed with bortezomib [65, 66].  
 Oprozomib (Onyx Pharmaceuticals, Inc.; ONX 1912; PR-047) is currently being 
tested in phase 1b/2 clinical trials for the treatment of multiple myeloma, and a phase 1 
study in patients with recurrent or refractory solid tumors (Figure 6). Oprozomib is an 
orally available epoxyketone analog which targets the chymotrypsin-like activities of 




Figure 6 Chemical structures of clinically relevant proteasome inhibitors. 
Bortezomib and carfilzomib are FDA approved for the treatment of multiple myeloma 
and refractory multiple myeloma, respectively. Oprozomib is in clinical trials for 
treatment of multiple myeloma as well as solid tumors. 
 
 
1.9 Proteasome Inhibitors of Individual Active Subunits  
  
 Subunit-specific inhibitory compounds are valuable tools for examining the impact 
of individual proteasome subunits on cell division and biological signaling pathways. The 
development of compounds with subunit specificities is often hindered by the strong 
inhibitory potency of most reactive functional head groups, such as boronic acids, or 
epoxyketones. Hence, only ligands that undergo optimal enthalpic interactions with the 
surrounding protein residues exert pronounced subunit selectivity.  
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 Historically, chymotrypsin-like (5) activities have been the focus for design of 
subunit specific inhibitors. Recently, however, a series of ’,’epoxyketone inhibitors 
which specifically target either caspase-like (1) or trypsin-like (2) sites of the 
constitutive and immunoproteasomes have been reported [38, 68] (Figure 7). In particular, 
the trypsin-like specific inhibitor NC-022 was shown to sensitize malignant cells to the 
chymotrypsin-like specific inhibitors bortezomib and carfilzomib, rendering them 
appealing co-targets for antineoplastic therapy.  
 Inhibition of the immunoproteasomes chymotrypsin like subunit (5i) with the 5i 
specific inhibitor PR957, has recently shown effectiveness in diseases such as rheumatoid 
arthritis, [69], experimental colitis [70], lupus erythematosus [71], and Hashimoto’s 
thyroiditis [72]. Whereas selective inhibition of 5i appears effective for the above 
mentioned diseases, inhibition of both constitutive and immunoproteasome 5 subunits 
was shown to be required to induce an antitumor effect in multiple myeloma, nonn-
hodgkin lymphoma, and leukemia cells [73].  
 Selective inhibition of the constitutive proteasomes 5 subunit, by the non-
covalent inhibitor PI-1840, has been shown to sensitize cancer cells to p53 and Bcl2 
antagonist [74]. Additionally, in vivo it was shown to suppress the growth in nude mice 
of human breast tumor xenografts [74]. This suggests that selective inhibition of 






Figure 7 Chemical structures of subunit specific proteasome inhibitors. PR-957 
targets immunoproteasome subunit 5i; PI-1840 targets constitutive proteasome subunit; 




1.10 Basic Crystallographic Theory 
 
1.10.1 Introduction to Crystallography 
 
X-ray crystallography is a biochemical technique for determining the three-
dimensional structure of macromolecules at atomic resolution.  The process of 
determining the structure is very labor intensive, and several hurdles must be overcome 
before arriving at your final protein model. The number of structures solved by either 
NMR, EM, or X-ray crystallography, and deposited to the Protein Data Bank (PDB) has 
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increased dramatically, with over 100,000 structures deposited as of June 2014; 89,277 of 
those being X-ray structures.  Due to advancements in computing, the volume of structures 
solved is expected to continue increasing at an exponential rate.  
 The first step to obtaining a crystal structure is to have a purified, homogeneous, 
and soluble protein from which you can obtain protein crystals. Protein crystals are 
necessary because a single protein molecule would not diffract radiation of high enough 
intensity. A protein crystal is composed of repeating identical unit cells, and the three-
dimensional components can be described by their repetition (Rhodes 1993).  Six 
parameters (unit cell parameters), are used to describe the unit cell: three axial lengths a, 
b, c and three interaxial angles ,,.  
 A protein crystal is exposed to x-rays over a small angle (typically 0.1-1 degree), 
and the diffracted x-rays are recorded by a detector, with one frame corresponding to a 
single rotation of the crystal. Diffraction is a direct consequence of Bragg’s law: 
2dhklsin = n 
where  is the angle of the impinging x-ray, n is an integer,  is the wavelength of the 
incident x-ray, and dhkl is the distance between two parallel planes of lattice points. When 
Braggs’s Law is satisfied, constructive interference occurs, producing the reflections, or 
spots, on the detector. An entire data set is collected when all unique reflections have been 
determined, by rotating the crystal around its center, resulting in several successive 
frames.  
 For every such diffracted x-ray that produces a diffraction spot, there is an 
associated amplitude and phase angle (Rupp, 2005). The amplitude and phase angle for 
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the diffracted x-rays represent the Fourier transform of the scattering density (electrons, 
in this case). A Fourier transform is a mathematical expression used to describe the 
harmonics of any repeating function, for example the repeating density of electrons from 
identical molecules that make up a crystal.  
 Electron density is obtained through translation of the diffraction data to obtain a 
structure factor equation [75]. The structure factor, Fhkl, is a function of the electron density 
distribution in the unit cell. The equation is a Fourier series that describes each reflection 
and contains one term corresponding to the contribution of each atom in the unit cell:  
Fhkl =  fje2i(hxj + kyj + lzj) 
where fj is called the scattering factor of atom j, and its value depends on what the element 
is (Rhodes, 1993). The contribution of each atom also depends on the amplitude of the 
contribution, and its position in the unit cell (xj, yj, zj) which establishes the phase of its 
contribution. Each reflection should be measured multiple times to insure a high degree 
of completeness and redundancy, thereby reducing systematic and statistical error. The 
intensity of the diffracted beam (h k l) is proportional to the square of the amplitude of the 
structure factor Fhkl:  
Ihkl =  Fhkl 2LP A 
where Ihkl is the integrated data in the form of intensities for each of the Bragg reflections, 
F is the structure factor, LP is a combined geometry and polarization factor and A is an 
absorption correction factor. The Fourier transform is used to convert the structure factors 
to (x,y,z), the desired electron density equation:  
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(x,y,z) = 1/V  Fhkle-2i(hx+ky+lz) 
where (x,y,z) is the electron density at the point with coordinates (x,y,z) in the unit cell, 
and V is the volume of the unit cell.  
 A full description of a diffracted ray must obtain three parameters: amplitude 
(which is proportional to the square root of the reflection intensity), frequency (which is 
that of the x-ray source), and phase (Rupp, 2005). The phase of each diffracted ray cannot 
be measured directly, but must be obtained in order to solve the structure, an issue referred 
to as the phase problem [76].  
 
1.10.2 Phase Problem and Molecular Replacement  
  
  There are several methods that can be employed to circumvent the phase problem, 
including; molecular replacement (MR), multiple isomorphous replacement (MIR), multi-
wavelength anomalous dispersion (MAD), single isomorphous replacement (SIR) and 
single anomalous dispersion (SAD) [77]. In isomorphous replacement methods, a heavy 
atom is soaked into the protein crystal, thereby changing the scattered intensity. Both a 
native (non-soaked) and a heavy metal soaked protein crystal must be collected and the 
intensities compared to gain a phase estimate. In anomalous dispersion methods, only a 
single crystal is needed and typically selenomethionine is used in place of methionine 
residues in the protein. Data can then be collected at several wavelengths near the 
absorption edge (in this case of selenium), resulting in an estimate of the phase, analogous 
to IR methods.  
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  Molecular replacement is a popular method for solving the phase angle, because 
it only relies on having a homologous protein, or search model, whose structure is known. 
The goal in molecular replacement is to orient and position the search model in the unit 
cell in a way that it coincides with the position of the unknown protein in the crystal. This 
requires the determination of six parameters; three angles, and three translational 
elements. There are two main steps which occur while placing the search model in the unit 
cell; a rotation function which determines the proteins orientation, and a translation 
function to determine the absolute position of the protein in the unit cell [78].  
For successful molecular replacement, the model should cover at least 50% of the 
total structure and the Cα r.m.s.d between the core model and the structure to be solved 
should be less than 2Å [79]. Additionally, most successful molecular replacements share 
at least 35% sequence identity between the protein of interest and the model [79].  Several 
computation programs are available for molecular replacement including Molrep [80] and 
AmoRe [81] of the ccp4 program suite, and Phaser [78] of the Phenix program suite. With 
the growing number of submitted protein structures in the protein data bank (> 86,000 x-
ray structures), and the expectation that there is a limitation to the number of possible folds 
for globular proteins, it is possible that at some point the phase of any new protein structure 
will be solvable by molecular replacement.   





1.10.3 Model Building and Refinement  
  
 Model building and refinement is the iterative process of constructing a protein 
model consistent with the observed data, and proceeds after phasing [82]. The initial 
calculated electron density map obtained from either molecular replacement or other 
phasing techniques is biased due to errors introduced during data collection, processing 
and phasing. 
  During refinement, structure factors are calculated (Fc) and compared to the 
observed structure factors (Fo) from the x-ray experiment. As the phases become more 
accurate during successive rounds of refinement, the calculated and observed structure 
factors should converge. This allows a means of assessing the quality of the structural 





Values of R range from zero, for a perfect agreement of calculated and observed 
intensities, to about 0.6, the R factor obtained when a set of measured amplitudes is 
compared with a set of random amplitudes (Rhodes, 1996).  
 Another measure of the structure quality is the free R-factor, or Rfree. This is 
calculated from a subset of reflections that are set aside prior to refinement, and used to 
assess the agreement between the calculated and observed models. It measures how well 
the structure predicts a subset of the measured intensities that were not included in the 
refinement [83].  
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 Aside from R factors, the chemical, stereo-chemical and conformational aspects 
of the structure are also monitored. Bond lengths and bond angles should fall near their 
accepted values, and these are assessed based on the root mean square deviations from 
ideal or accepted values (Rhodes, 2006). Completed models that are well refined should 
have root mean square deviations of no more than 0.02 Å for bond lengths, and 4o for bond 
angles (Rhodes, 2006). Monitoring the Ramachandran plot will insure the model meets 




2. STRUCTURAL STUDIES OF THE HUMAN 20S PROTEASOME* 
 
2.1 Results and Discussion   
 
2.1.1 Sequence Alignments  
  
The tertiary and quaternary structure of the 20S proteasome is highly conserved 
from archaea to mammals and it is assumed that its two types of subunits, termed α and 
β, evolved from a common ancestor protein [16, 19, 21]. The catalytically active 
subunits of human 20S constitutive and immunoproteasomes display high sequence 
identities to each other: β1c/β1i: 65%, β2c/β2i: 59%, β5c/β5i: 55%. The sequence 
identities between corresponding catalytic immunoproteasome subunits of mouse and 
human are: 90.5% (1i); 89% (2i); 92% (5i), with majority of the amino acid 
differences residing outside of the active sites.   
Although sequence alignments are indicative of an overall conserved fold for all 
proteolytically active subunits, defined differences in their substrate binding channels 
give rise to different cleavage preferences in the cCP, iCP and tCp [21]. In particular, 
hydrophobic amino acids in the unprimed substrate binding pockets of subunit β1i have 
been predicted to attenuate the caspase like activity and to increase the chymotrypsin 
                                                 
* Part of the data reported in this chapter is reprinted with permission from “Crystal Structure of the 
Human 20S Proteasome in Complex with Carfilzomib”, Harshbarger, W., Miller, C., Sacchettini, J. 
(2015), Structure, DOI 10.1016/j.str.2014.11.017, Copyright 2014 by Cell Press.  
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like activity [21], enhancing the generation of peptides with hydrophobic C-termini. 
Analysis of the alignments between subunits β2c/i and β5c/i give no indication of 
chemical changes in the substrates binding regions (Figures 8, 9 and 10).  
However, as shown in the immunoproteasome crystal structure from mouse, the 
S53Q amino acid substitution in iCPs results in a larger S1 pocket by stabilizing the 
Met45 side chain. The more spacious S1 pocket of immunoproteasomes is more suitable 
for large hydrophobic residues such as phenylalanine, and is suggested to result in 




Figure 8 Sequence alignments of proteasomes caspase-like (1) constitutive (c) and 
immuno (i) subunits from Homo sapien (hu), Mus musculus (mu), and T. 
acidophilum (y). Secondary structures (S: -sheet; H: helix) are indicated for the human 
constitutive subunits. Residues important for the active site are indicated with red boxes. 
Residues contributing to the substrate-specificity pockets are highlighted by colored 
boxes: S1 pocket, green; S2 pocket, blue; S3 pocket, yellow.   
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Figure 9 Sequence alignments of proteasomes trypsin-like (2) constitutive (c) and 
immuno (i) subunits from Homo sapien (hu), Mus musculus (mu), and T. 
acidophilum (y). Secondary structures (S: -sheet; H: helix) are indicated for the human 
constitutive subunits. Residues important for the active site are indicated with red boxes. 
Residues contributing to the substrate-specificity pockets are highlighted by colored 
boxes: S1 pocket, green; S2 pocket, blue; S3 pocket, yellow.   
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Figure 10 Sequence alignments of proteasomes chymotrypsin-like (5) constitutive 
(c) and immuno (i) subunits from Homo sapien (hu), Mus musculus (mu), and T. 
acidophilum (y). Secondary structures (S: -sheet; H: helix) are indicated for the human 
constitutive subunits. Residues important for the active site are indicated with red boxes. 
Residues contributing to the substrate-specificity pockets are highlighted by colored 






2.1.2 Purification, Crystallization and Structure Determination  
  
A strategy was developed in order to purify human 20S proteasome constitutive 
core particles (cCPs) from red blood cells, and is described in detail in Methods section 
2.3.1. The purification strategy was adapted from that used for the purification of the yeast 
20S proteasome by Groll et. al. [21] and resulted in greater than 95% purity, proven by 
SDS-PAGE (Figure 11).  To circumvent the large amount of hemoglobin in the initial 
lysed red blood cells (> 97% of total protein), dialysis with100 kD dialysis tubing 
(Spectrum) was carried out overnight against 4L of 10 mM Tris pH 7.5/1mM EDTA prior 
to affinity chromatography steps. This greatly reduced the concentration of hemoglobin in 
the protein solution and allowed for easier loading onto an anion exchange column. Early 
attempts forgoing dialysis resulted in clogged anion exchange columns (HiTrap Q HP, GE 
Healthcare). 
Purified cCPs were concentrated to 30mg/mL, and Mg2+ added to a final 
concentration of 50mM. The Mg2+ was added for initial crystal screens because 
proteasomes from bovine and yeast each crystallized in conditions containing Mg2+ [21]. 
The protein was subjected to sitting drop vapor diffusion crystal trials using a sparse 
matrix screen including; Emerald BioscienceWizard I/II; Hampton Research Crystal 
Screen I/II and Qiagen 2-Methyl-2,4-pentanediol (MPD) screen. The protein:reservoir 
ratio was 1:1 with a final drop volume of 1L. 
The first 20S proteasome crystals identified were in a Wizard condition containing 
10% polyethelyene glycol (PEG) 8000 and 0.2M NaCl; however, the crystals did not 
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diffract beyond 30 Å resolution using a home x-ray source, Rigaku R-Axis IV++(Figure 
12). In an attempt to optimize the crystal condition to increase resolution, the protein was 
set up with the addition of the Hampton Research Additive Screen, in a 1:1:0.5 ratio of 
protein:reservoir:additive, on a hanging drop plate. This was performed manually, with 
each protein drop containing a different additive. The additive screen is a library of 96 
reagents which include multivalent, salt, amino acid, dissociating agent, linker, polyamine, 
osmolyte, chaotrope, co-factor, reducing agent, chelating agent, polymer, carbohydrate, 
non-detergent, amphiphile, detergent, non-volatile organic and organic molecules. 
Cesium at a final concentration of 1mM changed the crystal morphology from 
rectangular crystals of approximately 1mm in length, to large squares that were 1mm thick 
and 3-4mm in length. The addition of cesium improved crystal diffraction to 16 Å. Next, 
crystals were dehydrated by increasing the percent of Peg 8000 in the reservoir solution 
by 1% per day to a maximum of 15% Peg 8000. Unfortunately, this method did not 
improve the diffraction of the crystals, therefore, it was decided to screen for a new 
condition that may result in better crystal packing and lead to higher resolution diffraction. 
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Figure 11 One-dimensional SDS-PAGE analysis of purified human proteasome 
constitutive core particles 
  
 A second round of crystal screening on Intelli 96 well sitting drop plates, without 
Mg2+ in the protein solution, identified several conditions from the Qiagen MPD (2-
Methyl-2,4-pentanediol) screen that produced crystals. Each condition contained 40% 
MPD and a different salt. Diffraction of the various crystals from the home X-ray source 
identified two conditions with resolution of 3.2 Å; 40% MPD, 0.2M sodium malonate; 
and 40% MPD, 0.2M sodium formate. Crystals were reproduced by hanging drop vapor 
diffusion using a 1:1 ratio of protein solution (30 mg/mL, 10mM Tris pH 7.5, 10mM 
EDTA) and crystallization buffer at 16oC. Crystals appeared in 7-10 days and grew to a 
maximum size of 0.3 mm (Figure 13). Crystals were then soaked in cryoprotecting buffer 
(30%MPD, 0.2M Sodium Formate) and flash frozen with liquid nitrogen prior to data 
collection at Argonne National Labs, beam-lines 19id and 23id.  On average, 
approximately 40 crystals were frozen because many crystals had anisotropic diffraction 
patterns and were not suitable for data collection.  
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Figure 12 Proteasome crystal and diffraction from condition containing Peg 8K, 




Figure 13 Proteasome crystals and diffraction from condition containing 40% MPD 
and 0.2M Sodium Formate.   
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 X-ray data for suitable crystals was collected and processed using HKL3000[84], 
described in Methods at the end of this chapter. The crystals space group was found to be 
P21 with unit cell dimensions of a = 119.2 Å, b = 205.1 Å, c = 163.1 Å and  = 106.4o 
Calculation of the Mathews coefficient in CCP4 [85] indicated a solvent content of 52%, 
assuming that the asymmetric unit contained only one proteasome core particle. 
Refinement with Phenix [86] resulted in a final structure with Rwork and Rfree values of 
0.21 and 0.24, respectively, with root-mean-square (rmsd) bond and angle values of 0.004 
Å and 0.81o, respectively. A Ramachandran plot indicated that greater than 95% of the 
backbone  and  angles were in acceptable conformation (Figure 14). Outliers occurred 
in alpha-helices and in regions where the electron density was not well defined.  Finalized 











Table 2 Crystallography Statistics  




Space group P 21  P  21  
Unit cell   
a (Å) 119.2 172.0 
b (Å) 205.1 201.0 
c (Å)  163.1 225.6    
β 106.4 107.93 
Data Collection   
Wavelength (Å) 0.97918 0.97918 
Resolution Range (Å) 50  - 2.6 (2.64  - 2.6) 50  - 2.9 (2.99  - 
2.89) 
No. observations 621008 1177627  
No. unique reflections 228370 321261  
Redundancy 2.7 (2.5) 3.7 (3.4) 
Completeness (%) 98.2 (91.8) 98.7 (91.7) 
I/Iσ 14.7 (2.1) 9.1 (1.1) 




Resolution range (Å) 33.5-2.59 33.5-2.89 
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Rwork 0.20  0.22  
Rfree 0.24 0.25 
Number of atoms 47831 96329 
  Protein 47646 95258 
  ligands - 572 
  water 185 499 
Protein residues 6286 12572 
RMSD   
Bond lengths (Å) 0.004 0.004 








2.1.3 Architecture of the Human 20S Proteasome Constitutive Core Particle  
 
 Evaluation of the proteasome in Coot [87] showed that the overall shape is an 
extended cylinder stretching approximately 150 Å in length with a diameter of about 115 
Table 2 continued 
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Å (Figure 18). The cylinder consists of twenty-eight total subunits, with seven unique  
and seven unique  chains, arranged in rings as 1-71-71-71-7. The organization and 
overall topology of the human proteasomes constitutive core particle (cCP) subunits is 
conserved among the eukaryotic proteasomes from yeast (PDB ID 1RYP) and bovine 
(PDB ID 1IRU).   
The entry gate to the central proteolytic chamber of the human cCP is closed by 
the N termini of the -subunits, which project into the pore of the -ring, forming several 
layers (Figure 19). Access to the core is regulated by ATPase’s, such as the 19S regulatory 
particle, or through an ATP dependent mechanism by association with PA28 [88, 89]. 
Superposition of the -ring of the human proteasome with the -ring from yeast, bovine, 
and mouse proteasomes illustrates high structural conservation (RMSD C atoms -ring 
< 0.59 Å for all -rings).               
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Figure 15 Quaternary structure of α-subunits. Subunit α5 is shown in ribbon 
representation, with each α-helix labeled as H, and β-sheets are labeled as S.  
 
Figure 16 Quaternary structure of β-subunits. All -type subunits have a similar 
arrangement of two -helices, H1 and H2, followed by two sets of five-stranded anti-
parallel -sheets, then two more -helices, H3 and H4. An additional two-stranded -
sheet is found in the loop connecting -strands S2 and S5. Subunit 5 (shown) has an 
additional two-turn -helix at its C-terminal end.    
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 All seven distinct - and -subunits have the same general -sandwich 
architecture, which is typical for N-terminal hydrolases [25].  In the -subunits, the -
sandwich consists of three -helices H1, H2 and H3, followed by two five-stranded anti-
parallel -sheets, then three additional -helices, H4, H5 and H6 on the opposite side 
(Figure 15). Differences among the seven -chains come in the length of the loop regions, 
and the number of turns in the -helices. Specifically, subunit 5 has a shorter -helix, 
H3, by two turns, followed by a longer insertion loop of nineteen residues from Ala120 to 
Val139, as opposed to only nine residues in the other six -type subunits. Subunits 3 and 
4 have a six-turn -helice, H6, whereas they are shorter by one to three turns in the other 
-subunits. The C-terminal ends of each -subunit after helix H6 are disordered and vary 
in length, containing mainly charged residues.   
 The -type subunits have an arrangement of two  helices, H1 and H2, followed 
by two sets of five-stranded anti-parallel -sheets, then two more -helices, H3 and H4. 
The anti-parallel -sheets are composed from -strands S1, S2, S10, S11, and S12 on one 
side, and by -strands S5 through S9 on the opposite side (Figure 16).  An additional two 
stranded anti-parallel -sheet is formed in the loop connecting -strands S2 and S5. 
Subunit 5 forms an additional two turn -helix, H5, at the C-terminal end from residues 




Figure 17 Conserved C-terminal loop of 2 subunits. The C-terminus of subunit 2, 
from residue Leu186 to Glu220, wraps around subunit 3 and forms an additional strand 
in its anti-parallel -sheet, S12. The black arrow indicates the C-terminus of 2. 
 
 The N-terminal residues of all -type subunits are buried in the core of the protein, 
whereas the C-terminal ends extend toward the second -ring.  The exception is the C-
terminus of subunit 2, from residue Leu186 to Glu220, which wraps around subunit 3 
and forms an additional strand in its anti-parallel -sheet, S12. This unique C-terminal 




Figure 18 Surface representation of the human 20 proteasome. Subunits are colored 
according to their symmetrical counterpart.    
  
       
Figure 19 Ribbon representation of top view of the α-subunits. The arrows indicates 
the entry to the catalytic chamber, which is closed off by the N-termini of the -
subunits. The 20S core can be activated by proteins such as the 19S regulatory particle, 
which inserts short C-terminal peptide segments into shallow pockets on the -ring 
surface, causing structural rearrangements. Each -subunit is colored uniquely.  
 49 
 
Figure 20 Structural alignment of proteasome catalytic subunits. Human (wheat), 
yeast (yellow) and mouse (teal).  
  
  
Superposition of individual catalytic -subunits of the human cCP with 
corresponding subunits of the mouse cCP, indicates that they adopt very similar folds 
(RMSD C atoms 0.38 Å for 1, 0.40 Å for 2 and 0.32 Å for 5), as does superposition 
with respective yeast catalytic subunits (RMSD C atoms 1.5 Å for 1, 0.65 Å for 2, and 
1.6 Å for 5) (Figure 20). This was expected, based on the high level of amino acid 
sequence conservation (> 95% with mouse cCP). The amino acid differences between 
active constitutive subunits of human and mouse proteasomes are surface-exposed, and 
PISA analysis indicates that the number and types of contacts between adjacent subunits 
differ; however, their impact on stability or half-life of the CPs cannot be determined from 
a structural perspective.  
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2.1.4  Subunit Post-Translational Processing and Catalytic Residues 
  
 Five of the seven -type subunits, including the three catalytic subunits (1, 2, 
and 5) are synthesized as pro-proteins, which are proteolytically processed to their 
mature forms found in the assembled core particle [91]. The mature, cleaved form of the 
proteasome was found for each β subunit in the human CP, indicated by no additional 
density at the N-terminus of each chain.   
 Subunit 6 is cleaved by 28 residues between Leu-1 and Arg1, and the 7 subunit 
is cleaved by 45 residues, between Arg-1 and Thr1, exposing an N-terminal threonine. 
Despite having an N-terminal Thr1, no definitive proof that subunit 7 is catalytically 
active has been established, although it was proposed to have hydrolase activity in the 
bovine crystal structure [92].   
  The nucleophilicity of Thr1 in each of the catalytic sites is enhanced via an 
elaborate network of hydrogen bonding with and between surrounding residues. The 
active sites are highly conserved and can be summarized by the chymotrypsin like site as 
follows: Thr1N is hydrogen bonded to Tyr169 O (2.9 Å), Ser130 O (3.1 Å), and Ser170 
O (3.1 Å); Lys33 N makes hydrogen bonding interactions with Thr1O (2.9 Å), Arg19 
O (2.7 Å), and Asp17 O1 (2.7Å); Asp17 O2 is hydrogen bonded to Ser18N (3.4 Å), and 
Gly171N (3.4 Å); and finally Asp17 O1 forms an additional hydrogen bond to Thr2N 




Figure 21 Active site of catalytic subunits β1, β2, and β5. Residues involved in 
catalysis are shown in magenta, and are conserved in all three distinct catalytic subunits. 
Hydrogen bonds are shown as black dashed lines, and the unique network increases the 
nucleophilicity of Thr1. Thr1 is shown in black, and the active site water, WAT, is 
shown as a yellow sphere. The water may be involved in intramolecular autolysis and 






2.1.5 Cleavage Preferences of Catalytic Subunits  
  
 In subunit 5, the residues in the S1 pocket that give rise to chymotrypsin-like 
activity are Ala20, Met45, Ala49, and Cys52. The S1 pocket in this site was found to be 
relatively shallow due to the side chain of Met45, located at the back of the pocket and not 
interacting with any surrounding residues. The S1 pocket of chymotrypsin like sites is able 
to accommodate hydrophobic residues such as alanine, valine, or tyrosine, consistent with 
cleavage of the known fluorogenic substrate Suc-LLVY-AMC (N-Succinyl-Leu-Leu-Val-
Tyr-7-amino-4-methylcoumarin) [93].  
 The S1 pocket in the caspase like site (1) is also shallow due to the side chains of  
residues lining the pocket; Thr20, Thr31, Thr35, Arg45, Ala49, Gln53 and 2Asp120. 
Positively charged Arg45, at the base of the S1 pocket facilitates accommodating acidic 
residues, and gives rise to the caspase-like activity. Subunit 1 can also cleave after some 
hydrophobic residues, thereby also contributing to the branched-chain amino acid 
preference activity of the proteasome [94, 95].    
 Subunit 2 is attributed with trypsin like activity. The base of the S1 pocket 
contains Gly45, resulting in a larger S1 pocket than 5 or 1 sites. Residues Cys31, His35, 
Asp53, and 3Cys129 give the region an overall acidic character, leading to a preference 
for basic residues such as Lysine or Arginine in the P1 position of substrates. This is 
consistent with trypsin like sites ability to cleave the known fluorogenic substrate Boc-
LLR-AMC [93] (Figure 22). 
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Figure 22 S1 specificity pockets of the catalytic β-subunits.  
 
2.2 Materials and Methods  
 
2.2.1 Proteasome Purification 
  
The constitutive 20S proteasome was purified from human erythrocytes. Red 
blood cells, isolated from 500 mL of whole blood and suspended in saline solution, were 
obtained from Gulf Coast Regional Blood Center, College Station, TX. Cells were pelleted 
by centrifugation for 10 minutes at 35,000 x G in a JA-25.50 fixed-angle Beckman rotor, 
the supernatant discarded, and the red blood cells resuspended in lysing buffer (20mM 
Tris pH 7.0, 50mM MgCl2, 1mM EDTA). The protein was then extracted with French 
press and the lysate centrifuged at 53,300 x G for 1 hour in the JA-25.50 rotor. The 
supernatant was dialyzed overnight at 18 oC in 100kD dialysis tubing (Spectrum Labs) 
against 4L of 10mM Tris-HCl pH 7.5, 1mM EDTA. The dialyzed protein was again 
centrifuged at 53,300 x G for 1 hr and the supernatant filtered with a 0.2 µm syringe filter 
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before being loaded onto a HiTrap QHP anion exchange column (GE Healthcare), pre-
equilibrated with buffer A (10 mM Tris pH 7.5, 1 mM EDTA, 350 mM NaCl). The column 
was washed with at least 5 column volumes of buffer A, then bound protein was eluted 
with a gradient of Buffer B (0-100%) (10mM Tris pH 7.5, 1mM EDTA, 700 mM NaCl). 
Fractions were analyzed by SDS-PAGE and those containing proteasome were pooled 
together and diluted 10 fold in Buffer C (10mM Tris pH 7.5, 1mM EDTA). Solid 
ammonium sulfate (> 99% pure from Sigma) was added to the pooled protein fractions at 
a final concentration of 40% saturation (w/v) while stirring with a magnetic rod on a stir 
plate at 18 oC. The solution was centrifuged for 10 minutes at 1600 x G in a bench top 
Eppendorf 5702 centrifuge, and the supernatant filtered with a 0.2 µm syringe filter before 
loading onto a HiTrap Phenyl Sepharose FF column (GE Healthcare), pre-equilibrated 
with Buffer D (10mM Tris pH 7.5, 1mM EDTA, 1.2M ammonium sulfate). The column 
was washed with 5 column volumes of Buffer D, then column bound protein was eluted 
with a gradient of Buffer C (0-100%). Fractions were analyzed by SDS-PAGE and those 
containing proteasome were pooled and dialyzed overnight at 18 oC  in 100 Kd dialysis 
tubing against Buffer C. Last, the protein was concentrated to 30 mg/mL for crystallization 
trials, using Spin-X UF 200 20mL concentrating tubes with a 100Kd MWCO purchased 






2.2.2 Crystallization of Human 20S Proteasome Constitutive Core Particle 
  
Purified proteasome (section 2.2) at a concentration of 30 mg/mL was screened for 
crystallization conditions in 96-well sitting drop Intelli-Plates (Art Robbins Instruments). 
The following crystallization buffers were screened: Emerald BioscienceWizard I/II; 
Hampton Research Crystal Screen I/II; Qiagen 2-Methyl-2,4-pentanediol (MPD) screen. 
Screening plates were set up using a Phoenix liquid handling robot (Art Robbins 
Instruments) to deliver 50µL of screening buffer to the appropriate reservoirs, followed 
by a mosquito (TTPlabtech) which delived 1µL of reservoir solution and 1µL of protein 
onto the sittling drop platform. Plates were manually sealed with ClearSeal Film 
(Hampton Research), and placed on a vibration free table at 16oC. The plates were checked 
for the formation of crystals at time intervals of 24 hours, 48 hours, 96 hours, and then 
once weekly.  
Crystals grew in the crystallization buffer of 0.2 M sodium formate, 40% MPD 
and were optimized by hanging drop vapor diffusion. Hanging drops consisted of either 
1:1 or 1:2 ratios of protein to crystallization buffer and placed on a vibration free table at 
16oC. Crystals appeared in 7-10 days and grew to a maximum size of 0.3 mm. Crystals 
were then soaked in cryo-protecting buffer (30%MPD, 0.2M Sodium Formate) and flash 
frozen with liquid nitrogen prior to data collection. Data was collected using synchrotron 
radiation at the Advanced Photon Source (Argonne National Labs, IL) with = 0.97918 
Å, at beam-lines 23iD and 19iD.    
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2.2.3 Data Collection, Processing and Structure Determination 
  
X-Ray intensities were indexed and scaled using HKL3000 [84] in the P21 space 
group. Data resulted in 621008 reflections, with 228370 unique reflections and overall 
completion of 98.2%. Calculations of the Matthews coefficient using ccp4 [96] gave an 
approximate solvent content of 50%, assuming one core particle in the asymmetric unit. 
The phase of the data was solved by molecular replacement using the default settings for 
the program Phaser [78] of the Phenix program suite [82], with the coordinates of the core 
particle from Bos Taurus (PDB ID 1IRU) as a starting model, and a sequence identity of 
100%, because the Bos Taurus structure contains the human proteasomes amino acid 
sequence in place of its own, due to the amino acid sequence not being known at the time 
of its publication.  This yielded a single solution which was used for structure refinement.   
 The proteasome structure was refined using  Phenix Refine version 1.82 [86]. 
Three cycles of coordinate, restrained atomic displacement parameters (ADP), translation-
libration-screw-rotation (TLS), and occupancy refinement were used with default settings, 
along with 2-fold non-crystallographic symmetry (NCS) averaging (cartesian). This was 
followed by manual real space-refinement in COOT [87], then three more rounds of 
refinement in Phenix with the above settings as well as individual B–factor, and TLS. 
Final Rwork and Rfree values were 0.21 and 0.24, respectively. Bond and angle values were 
0.004 Å and 0.81o, and the Ramachandran plot indicated that 96% of backbone dihedral 
angles were in allowed conformations.  The finalized structure was deposited and accepted 
in the Protein Data Bank under accession numbers 4R3O.  
 57 
2.2.4 Bioinformatics Tools  
 
Protein sequences were obtained from the “Universal protein resource” 
(www.uniprot.org). Alignment of protein homologs was performed with ClustalW2 
(www.ebi.ac.uk/Tools/msa/clustalw2/).   
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 Carfilzomib is the result of medicinal chemistry efforts focused on increasing the 
potency and chymotrypsin-like selectivity of epoxomicin. It is a synthetic tetrapeptide 
expoxyketone, and was approved in July 2012 for use in patients with multiple myeloma 
who have received at least two prior therapies.  Structural information on the yeast core 
particle alone and in complex with epoxomicin strongly supported its development [61].  
 Drug discovery has also been facilitated by structure activity relationship studies 
which show that subunit selectivity can be achieved by varying the substituents of a drug 
at the P1 position, as has been shown for lactacystin [97] and salinosporamides [98],  and 
by varying the P3 substituent, shown by vinylsulfone-inhibitors (Groll et al., 2002; Nazif 
and Bogyo, 2001). Additionally, the substitution of hydrophobic or aromatic groups in the 
P4 position has been shown to lead to trypsin like selectivity [99, 100].  Crystal 
structures of the yeast:epoxomicin (Groll et al., 2000) and yeast:PR-957 (Groll et al., 
2012) proteasome complexes have shown that the epoxyketone pharmacophore inhibits 
via covalent adduct, forming a morpholino ring with Thr1N and Thr1O. The ring 
formation occurs in a two-step process. First, a reversible hemiketal is formed by attack 
                                                 
* Part of the data reported in this chapter is reprinted with permission from “Crystal Structure of the 
Human 20S Proteasome in Complex with Carfilzomib”, Harshbarger, W., Miller, C., Sacchettini, J. 
(2015), Structure, DOI 10.1016/j.str.2014.11.017, Copyright 2014 by Cell Press.  
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of Thr1O with the ketone group of CFZ. Next, the epoxide is nucleophilically attacked 
by the amine group of Thr1, resulting in an irreversible intermolecular cyclization, which 
yields the morpholino ring (Figure 23) [16].  
 The morpholine ring system that results is irreversible and leads to a higher degree 
of specificity for the proteasome, with minimal off-target effects thereby decreasing side 
effects such as neurotoxicity. Additionally, the irreversible nature of CFZ inhibition may 
be a contributing factor to its ability to overcome both primary and secondary resistance 
to bortezomib [101]. Despite this, some drawbacks of CFZ are its relatively poor 
bioavailability, and a half-life of less than 30 minutes [66, 102], making it imperative that 
next generation proteasome inhibitors be designed that have greater stability and enhanced 
cellular uptake.  
 
 
Figure 23 Proteasome reaction mechanism against epoxyketone inhibitors.  The 
carbonyl carbon atom is attacked by the proteasomes Thr1O nucleophile. The formed 
hemiketal intermediate can either dissociate to deliberate Thr1Oγ or irreversibly cycle 
under the formation of a secondary amine (morpholine ring system) involving Thr1N. 
  
 CFZ primarily targets the chymotrypsin-like activity of the constitutive 
proteasome (5c), with five times the selectivity over the immuno proteasome subunit 5i 
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(IC50 of 6nM against 5c and 33nM against β5i) [66]. Caspase-like and trypsin-like sites 
were shown to be less inhibited, with IC50 values of 2400 nM and 3600 nM, respectively 
[66]; however, the chymotrypsin-like inhibition is attributed with the drugs anti-cancer 
effects.  
 The structural investigation of the proteasome:carfilzomib complex presented in 
this chapter aims to elucidate the answers to two questions: what are the structural features 
that give rise to chymotrypsin-like selectivity over caspase-like and trypsin-like sites; and 
what is the cause for increased selectivity of constitutive proteasome chymotrypsin-like 
sites over immunoproteasome?   
 
3.2 Results and Discussion  
 
3.2.1 Carfilzomib Binding  
  
 In order to determine the molecular basis for the chymotrypsin-like specificity of 
carfilzomib, human proteasome crystals were soaked with 5mM of the drug for 12 hours 
before exposure to synchrotron radiation for data collection.  Two crystal conditions 
produced diffraction to greater than 3Å; sodium formate/40% MPD, and sodium 
malonate/40% MPD. The condition containing sodium formate as the salt produced the 
more durable crystals, because it was found that the malonate crystals would quickly 
dissolve once the hanging drops were exposed to air. This made it very difficult to soak 
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the crystals with inhibitor, therefore, sodium formate crystals were chosen for inhibitor 
bound structure determination.  
Data was collected and processed using HKL300, as described for the apo 
proteasome structure, at Argonne National Labs, Chicago, Il. Molecular replacement with 
the program Phenix was used to solve the phase, using the coordinates of the proteasome 
core particle from Bos Taurus (PDB ID 1IRU) as a starting model. Refinement with 
Phenix led to Rwork and Rfree values 0.23 and 0.2, respectively (described in Methods at the 
end of this chapter). Bonds and angles were also good, with values of 0.002 Å and 0.6o, 
respectively. Carfilzomib was generated using PRODRG, and fit into the Fo-Fc density 
manually in COOT. Coordinates for finalized structures were confirmed to have good 
stereochemistry from the Ramachandran plot, with greater than 98% residing in allowed 
regions (Figure 25).  
 The difference electron density map for CFZ soaked crystals indicated that CFZ 
had targeted all four chymotrypsin-like and trypsin-sites, and three of the four caspase-
like sites in the asymmetric unit, through covalent binding to Thr1 (Figure 24). Subunit 
7, which was proposed to have hydrolase activity, did not have the inhibitor bound, 
therefore whether it is an active subunit remains elusive.  
 Carfilzomib modified Thr1 in each inhibited subunit via a dual covalent adduct 
with its C-terminal epoxyketone (Figures 26-28). A morpholino ring is formed with Thr1N 
and Thr1O, which is consistent with proteasome inhibition by other epoxyketone 
inhibitors such as epoxomicin (Groll et al., 2000) and PR-957 (Groll et al., 2012). The 
electron density map reveals an ordered water molecule located 3.5 Å from Ser130N in 
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all three catalytic sites, which forms a 3.0 Å hydrogen bonding interaction with the P1 
carbonyl. The water molecule is also suggested to be involved in both intramolecular 
autolysis and substrate proteolysis by mediating proton transfer between Thr1O and 
Thr1N [21].     
The C-terminal end of CFZ completes an anti-parallel -sheet in each of the 
proteasome binding channels with the conserved amino acids Thr21, Gly47, and Ala49 
(Figures 29, 30, 31). Although the residues that form the hydrogen bonds are conserved 
in all three catalytic centers, the hydrogen bonding distances differ between subunits. The 
hydrogen bonds can be summarized for the caspase-like sites as follows; Thr21N (3.3 Å), 
and Thr21O (2.9 Å) of -strand S3 on one side of the binding pocket, and Gly47O (2.7 Å) 
and Ala49N (3.4 Å) from the loop connecting S6 and H1 on the other side of the binding 
pocket. In trypsin-like sites the hydrogen bond distances are; Thr21N (3.3 Å), Thr21O 
(2.9 Å), Gly47O (3.0 Å), and Ala49 N (2.7 Å); and in the chymotrypsin-like sites, Thr21N 
(3.2 Å), Thr21O (2.9 Å), and Gly47O (2.7 Å).  
A second water molecule (WAT) found in the chymotrypsin-like site makes a 2.5 
Å hydrogen bond with the P3 carbonyl oxygen of carfilzomib, replacing the hydrogen 
bond from Ala49 N, and results in a shorter hydrogen bond distance by ~0.5 Å. The water 
is also hydrogen bridged with A49N (3.0 Å), A50N (2.9 Å), and 6D125O 2 (3.2 Å). 
The water molecule was reported in the yeast:bortezomib crystal structure, but was not 
described in the mouse immunoproteasome or constitutive proteasome complexes with 
the epoxyketone inhibitor PR-957, therefore whether or not it is important for 
chymotrypsin-like selectivity of inhibitors is ambiguous. 
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Figure 24 View of the inner cavity of the human 20S proteasome with carfilzomib 
bound. The 4 and 4-subunits have been removed to give a view of the core of the 20S 
proteasome. Carfilzomib, shown as green sticks, is bound to all six active sites.  
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Figure 25 Ramachandran plot for carfilzomib bound human 20S proteasome. 
 
 The N-terminal morpholino moiety of CFZ is not engaged in any interactions with 
the protein in any of the catalytic sites. However, in chymotrypsin-like and trypsin-like 
sites the backbone of carfilzomib is curved approximately 45 degrees relative to caspase-
like sites (Figure 32). This change in orientation is due to steric effect caused by the side 
chains of 3Glu106 and 6Tyr107 in trypsin-like and chymotrypsin-like binding regions, 




Figure 26 Surface representation and electron density of carfilzomib bound to the 
chymotrypsin-like active site. Thr1 is colored black; carfilzomib is colored green; 
electron density is blue and is contoured to 1.  
 
 An additional hydrogen bond is found in the chymotrypsin-like and trypsin-like 
sites, between Asp125O 2 of the adjoining subunit (6 and 3, respectively) and CFZ’s 
P3 peptide bond, with distances of 3.2 Å and 2.7 Å, respectively. This interaction is 
missing in caspase like sites, where the aspartate residue is replaced by Tyr114, which is 




Figure 27 Carfilzomib bound to the trypsin-like subunit, 2.  
 
 




Figure 29 Hydrogen bonding interactions of carfilzomib in the chymotrypsin like 
subunit β5. Hydrogen bonds are indicated with black dashed lines; the active site water 
molecules are shown as red spheres. The nucleophilic Thr1 is shown in black.  
  
 
In trypsin like sites the P4 carbonyl oxygen forms a 3.0 Å hydrogen bond with 
3Glu106 O2 from the adjoining 3 subunit (Figure 30). The analogous residue in 
chymotrypsin-like sites is 6Tyr107 which does not hydrogen bond with carfilzomib, and 
in caspase-like sites the nearest residue is 2 His116, however at 4.6 Å to the nitrogen, it 
is also insufficient for hydrogen bonding.   
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Figure 30 Hydrogen bonding interactions of carfilzomib in the trypsin-like subunit 
β2. Hydrogen bonds are indicated with black dashed lines; the active site water 
molecules are shown as red spheres. The nucleophilic Thr1 is shown in black.    
 
   
Figure 31 Hydrogen bonding interactions of carfilzomib in the caspase-like subunit 
β1. Hydrogen bonds are indicated with black dashed lines; the active site water 




Figure 32 Structural alignment of chymotrypsin-like and caspase-like sites with 
carfilzomib bound. In caspase-like sites, H116 prevents carfilzomibs P4 phenyl group 
from accessing the S4 pocket (black arrow), resulting in a disordered N-terminus of the 
drug and decreased selectivity. The N-terminal morpholino ring in chymotrypsin-like 
sites assumes a fixed conformation due to steric effects of Y107.  
 
   
3.2.2 Interactions of Carfilzomib with Proteasome Specificity Pockets 
 
A detailed evaluation of the active subunits in the presence and absence of 
carfilzomib visualized the structural features that lead to the drugs chymotrypsin-like 
selectivity. In caspase-like sites, the N-terminus of carfilzomib, beginning at the P4 phenyl 
group, is not well-defined in the electron density. Comparison with chymotrypsin-like and 
trypsin-like sites reveals that His116 of chain 7 acts to sterically block carfilzomibs P4 
phenyl group from entering the S4 pocket of caspase-like sites. Structural alignment with 
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either chymotrypsin-like or trypsin-like subunits shows that the P4 substituent of CFZ is 
shifted by up to 3.7 Å away from the S4 pocket. Additionally, the P4 phenyl group of 
caspase-like sites makes no interactions with the protein. In contrast, chymotrypsin-like 
and trypsin-like sites each have S4 pockets that favor the hydrophobic P4 phenyl group of 
carfilzomib.  Van der Walls interactions are made with the side chains of 6Val127 (4.0 
Å) in chymotrypsin-like sites and 3Ile126 (3.8Å) and 3Ile127 (4.0 Å) in trypsin-like 
sites.  
 The P3 position of CFZ contains leucine which is able to make Van der Waals 
interactions in each of the three distinct catalytic subunits. In chymotrypsin like sites, the 
S3 pocket has four hydrophobic amino acid side chains that surround the P3 leucyl and 
make Van der Waals contacts as follows; Ala20 (3.9 Å), Ala22 (4.4 Å), Ala27 (3.9 Å) and 
the aliphatic side chain carbon of 6Asp125 (3.6 Å). Caspase-like sites make Van der 
Waals contacts with the side chains of Ala27 (3.3 Å), Thr20 (4.0Å), Thr22 (4.3 Å) and the 
phenyl ring of β2Tyr114 (3.7 Å). In trypsin like sites, the Van der Waals interactions come 
from the side chains of Ala27 (4.3 Å), Ala20 (4.4 Å), and the aliphatic carbon of Glu22. 
The acidic side chain of 3Asp125, however, also lines the S3 pocket of trypsin-like sites; 
therefore binding at the P3 position is less favorable than chymotrypsin-like and caspase-
like subunits.  
 The S2 pockets of all three active sites are able to accommodate the P2 
phenylalanine moiety of CFZ, and no contacts are made with the protein. The crystal 
structure of bortezomib bound to the yeast proteasome shows that its P2 phenylalanine 
ring is flipped toward Thr1 in both the chymotrypsin-like and caspase-like sites, and away 
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from Thr1 in the trypsin-like sites [42] (Figure 33).  In contrast, the human 
proteasome:CFZ complex shows the phenyl ring is flipped away from Thr1 in all three 
distinct catalytic centers. Carfilzomibs P2 substituent assumes the same orientation taken 
by the P2 methoxyphenyl substituent of PR-957 in the mouse immuno and constitutive 
proteasome structures [16].  
 
Figure 33 Structural alignment of the chymotrypsin-like sites of the 
human:carfilzomib, yeast:bortezomib, and mouse:PR-957 complexes. The black 
arrow indicates the P2 residue, which is flipped in carfilzomib (green) and PR-
957(white) relative to the P2 phenylalanine of bortezomib (pink). Thr1 is shown in 
black, and the specificity pockets which harbor ligand side chains are labeled as S1-S4. 
 
  The S1 pocket of chymotrypsin-like subunits makes van der Waals contacts with 
CFZ’s P1 leucyl from the side chains of Ala49 (3.7 Å), Val31 (4.5 Å), Ala20 (3.5 Å), and 
Met45 (4.3 Å). Structural alignment of unbound and CFZ bound proteasome (rmsd Cα: 
0.4 Å) reveals that upon binding of CFZ, the P1 leucyl group causes the side chain of 
Met45 to shift by 2.7 Å towards Ile35, which is then shifted by 1.7 Å (Figure 34). In 
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contrast to caspase-like subunits where Arg45 is hydrogen bonded and unable to 
accommodate the leucyl group, the Met45 side chain is not stabilized by surrounding 
residues and is therefore flexible. Upon shifting of the Met45 and Ile35 side chains, 
conformational changes involving residues 34 to 72 are also seen. This offsets β-sheets S4 
and S5 as well as α-helix H1 compared to the unbound structure.  
 In summary, caspase-like sites disfavor CFZ binding due to electrostatic and steric 
effects at the P1 and P4 positions, respectively, while chymotrypsin-like and trypsin-like 
sites show similar hydrogen bonding and Van der Waals interactions. The most profound 
difference between chymotrypsin- and trypsin-like sites is the size of the S1 pocket, and 
the number of van der Waals contacts made with the P1 leucyl of CFZ. This may suggest 
the importance of a properly stabilized P1 substituent for modification of Thr1 by the 
epoxyketone pharmacophore.  Despite these seemingly minor differences, CFZ is nearly 
1000-fold more potent toward chymotrypsin-like subunits. An additional explanation may 
be accessibility. It is interesting to note that the IC50 for trypsin-like sites of 
immunoproteasomes is reduced to 620 nM (Screen et al., 2010), which may be a reflection 
of better accessibility in immunoproteasomes, considering that active site substitutions 
between the two isoforms do not appear to change the character of the binding region. 
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Figure 34 Shifts in the S1 pocket of the human proteasome chymotrypsin-like 
subunit, 5, upon carfilzomib binding. Unbound and carfilzomib bound structures are 
aligned by their C atoms. The unbound 5 is colored white, carfilzomib bound 5 is 
wheat, carfilzomib is colored green, and Thr1 is black. Regions of the protein that shift 
upon carfilzomib binding are indicated with black arrows.  
 
 
3.2.3 PR-957 Selectivity for Immunoproteasome  
  
The residue and loop movements in the chymotrypsin-like S1 pocket of the 
constitutive proteasome:carfilzomib complex were also reported in the crystal structure of 
the mouse constitutive proteasome:PR-957 complex, but not in the mouse 
immunoproteasome:PR-957 structure [16] (Figures 35 and 36, respectively). In the 
immunoproteasome chymotrypsin-like subunit, the side chain of Met45 in the S1 pocket 
is stabilized by the aliphatic side chain of the conserved amino acid substitution Q53, 
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resulting in a larger S1 pocket than constitutive S1, and therefore no need for 
rearrangement. Although the shifts in the S1 pocket of the mouse constitutive 
proteasome:PR957 complex were suggested to be the cause for immunoproteasome 
selectivity [16], carfilzomib is slightly more selective for constitutive proteasomes than 
immunoproteasome (IC50 = 6nM and 34 nM, respectively) even though this structural 
rearrangement occurs. To investigate this discrepancy, we compared the mouse 
constitutive proteasome:PR-957 complex with the human constitutive 
proteasome:carfilzomib structure to examine the interactions in the entire binding region, 
and determine the complete nature of the selectivity in each case.  
 
    
Figure 35 PR-957 bound to mouse constitutive 20S Proteasome chymotrypsin-like 
site. The same structural rearrangements are observed as in the carfilzomib:proteasome 
structure, indicated with black arrow.  The unbound protein is teal, PR-957 bound is 




Figure 36 PR-957 bound to mouse 20S immunoproteasome chymotrypsin-like site. 
Same color scheme as figure 36. No structural rearrangements are observed due to 
Gln53 stabilizing Met45 resulting in a larger S1 pocket than constitutive proteasomes β5 
(PDB ID unbound, 3UNH; PR-957 bound, 3UNF).  
  
The most profound differences reside at the P4 and P3 positions of the two drugs. 
PR-957 is a tripeptide epoxyketone and is unable to make interactions with the S4 binding 
pocket, whereas carfilzomib makes van der Waals interactions with 6Val127. 
Additionally, PR-957 contains a P3 alanine, opposed to carfilzomibs P3 leucyl group. 
While this maintains a hydrophobic nature, the distances of PR-957s alanine to the residue 
side chains in the S3 pocket are up to 1.9 Å greater (Ala20) than those of carfilzomibs P3 
leucyl group (Figure 37). Taken together, this suggests that PR-957’s selectivity for 
immunoproteasomes is only partially explained by immunoproteasomes having a larger 




Figure 37 Carfilzomibs P3 and P4 residues contribute to its increased selectivity for 
constitutive proteasomes chymotrypsin-like sites compared to PR-957. Carfilzomib 
(left image) has a P3 leucyl group and P4 phenyl group which stabilize ligand binding. 
PR-957 (right image) has a smaller alanine at P3 and no P4 residue, resulting in 
decreased selectivity towards constitutive proteasomes chymotrypsin-like sites and more 
favorable binding to immunoproteasomes.  
  
The human proteasome:carfilzomib structure suggests that it is also an absence of 
interactions in PR-957’s P3 and P4 positions which contributes to its selectivity for 
immunoproteasomes, whereas CFZ, which does have favorable interactions at the P4 and 
P3 positions, is able to maintain selectivity for constitutive proteasomes despite structural 
rearrangements in the S1 pocket.  
  
3.2.4 Predictions of Carfilzomib Interactions with the Immunoproteasome 
   
In most cells, upon exposure to interferons (IFNs), the β1i/LMP2, β2i/MECL-1, 
and β5i/LMP7 subunits are induced and incorporated into newly synthesized 
immunoproteasomes, taking the place of the constitutive catalytic subunits 1,2, and 5 
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[103]. Cleavage preferences for immuno CPs are after nonpolar amino acids, therefore the 
peptides produced have hydrophobic C termini which then bind to MHC-1 molecules 
[104, 105].  
 The immunoproteasome is a major form of the proteasome expressed in cells of 
hematopoietic origin, including multiple myeloma tumor cells. Despite being expressed 
in higher levels than constitutive proteasomes, specific inhibition of either proteasome 
form alone has been shown to be insufficient at producing an antitumor response in 
CD138+ multiple myeloma cells; rather, inhibition of both forms is necessary [73].
 Recent studies also show that high levels of immunoproteasomes are associated 
not only with various types of cancer, but also in autoimmune disorders and 
neurodegenerative diseases [106-109]. Therefore, the design of immuno proteasome 
selective inhibitors is now being explored as novel therapeutics to combat these diseases.  
  Structural alignments of the 1 (caspase-like), 2 (trypsin-like), and 5 
(chymotrypsin-like) subunits of the carfilzomib bound constitutive human proteasome, 
with the corresponding immuno subunits of M.mucus (mouse) shows high structural 
similarity; rmsd C: hu5c/mu5i  0.59Å; hu1c/mu1i  0.56Å; hu2c/mu2i  0.63Å. 
The sequence identities between the human constitutive and mouse immunoproteasome 
catalytic subunits are 70% (5), 64% (1) and 58% (2). The sequence identities of the 
catalytic immunoproteasome subunits between the two species are: 90.5% (1i); 89% 
(2i); 92% (5i), with majority of the amino acid differences residing outside of the active 
sites.    
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 To investigate why carfilzomib’s IC50 is lower for binding to the chymotrypsin-
like subunits of constitutive proteasomes over immunoproteasomes, the carfilzomib 
bound chymotrypsin-like subunit (5) was structurally aligned with the mouse 
immunoproteasome chymotrypsin-like subunit (5i) (rmsd C = 0.59 Å) (Figure 38). The 
amino acid sequence similarity between the two subunits is 92%, and they share five 
conserved amino acid substitutions in the substrate binding region. Conserved amino acid 
substitutions in the chymotrypsin-like sites of human and mouse constitutive and 
immunoproteasomes are: V128T, A46S, G48C, S53Q and A27S. The structural alignment 
revealed that the conserved substitution G48C places the polar cysteine side chain 3.2 Å 
from carfilzomibs P4 phenyl group. Additionally, the conserved substitution A27S, places 
the polar side chain of serine within 3.3 Å of the P3 leucyl group. Given the importance 
of the P3 and P4 positions in the IC50 value, as indicated previously for PR-957, it is 
possible that these minor changes could account for the nearly 6 fold increase in the IC50 
value between immuno and constitutive proteasomes, respectively. 
 Amino acid substitutions in the binding region of human immunoproteasome 
chymotrypsin-like (5i) sites that are not present in mouse immuno proteasomes include 
S28A, and T21S. These remain in mouse 5i as serine and threonine, respectively. While 
the T21S substitution maintains similar polarity as constitutive core particles, the S28A 
substitution is in the S3 pocket and increases the hydrophobicity compared to mouse 
immunoproteasome 5i. Additionally, mouse 5i subunits have a V31M substitution in 
the back of the S1 pocket, whereas residue 31 remains a valine in human. This maintains 
hydrophobic character, but results in a larger S1 pocket for human 5i.  
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 In caspase like sites of the immunoproteasome (1i), the conserved amino acid 
substitutions in the S1 pocket are T20V, T31F, R45L, and T52A (Figure 40). This results 
in a decreased size and increased hydrophobicity of the S1 pocket of 1c. This leads to a 
preference for cleavage after small, hydrophobic and branched residues, consistent with 
cleavage of the model substrate Ac-PAL-AMC (Acetate-Pro-Ala-Leu-7-amino-
methylcoumarin)[110-112]. This results in the generation of more epitopes with nonpolar 
C termini such as Ile, Leu, or Val, which are presented on MHC-1 molecules. Other 
conserved substitutions in the binding region of 1i are located in the S3 pocket. T22A 
increases the S3 pockets hydrophobicity, and A27V conserves hydrophobic nature but 
provides a larger surface, providing more contact space. The substitution Y114H of 
adjoining subunit 2i, however, adds polarity to the S3 pocket, but does increase it in size 
relative to 1c, where the tyrosine blocks off the S3 pocket. Whereas mouse proteasomes 
have the substitution 2S112E, which is located in the back of the S3 pocket, humans have 




Figure 38 Structural alignment of the chymotrypsin-like subunit β5c of the human 
proteasome:carfilzomib complex with the corresponding mouse immuno subunit 
β5i.  The human proteasome subunit is shown in wheat; carfilzomib is shown in green; 
the active site Thr1 from human is shown in black; mouse immuno subunit is shown in 
white. Conserved amino acid substitutions are shown as white sticks and labeled in 
black. Residue substitutions not conserved with human β1i are shown as black sticks, 
with the human substitution shown in black in parenthesis. Red labels are of the 
constitutive particle residue that is substituted.     
 
In trypsin-like subunits (1) the S1 pockets of human and mouse have the 
conserved substitution D53E, as well as the substitution in the S2 pocket T48V, the later  
increasing the hydrophobicity of S2 relative to constitutive proteasomes. Structural 
comparison of the mouse immuno proteasome subunit with the CFZ bound human 
proteasome, shows that the valine 48 substitution would project the valine side chain 
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within 3.5 Å of CFZ’s P2 phenylalanine ring, and would be able to make Van der Waals 
interactions (Figure 39). Additionally, the conserved substitutions G23D and E22N are 
located near the N-terminus of CFZ, and the structural comparison indicates that the 
aspartate substitution would result in the side chain O2 atom being within 2.9 Å of the 
CFZ N-terminal morpholino oxygen, which is within hydrogen bonding distance. Human 
immuno proteasomes have an additional substitution of T52A in the S1 pocket, located 
4.5 Å from the P1 leucyl of CFZ, increasing the hydrophobicity of S1and providing 





Figure 39 Structural alignment of the trypsin-like subunit β2c of the human 
proteasome:carfilzomib complex with the corresponding mouse immuno subunit 
β2i. The same color scheme is used as Figure 40.    
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Figure 40 Structural alignment of the human caspase-like subunit β1c with the 






 The proteasome is at the center of protein degradation for more than 90% of 
cytosolic proteins, which are oxidatively damaged, mis-folded, or tagged by ubiquitin for 
proteolysis. As such, the proteasome has been the focus of drug discovery efforts, which 
take advantage of the proteasomes essentiality for cellular homeostasis and are proven 
targets in various forms of cancer, namely multiple myeloma. Previous structural studies 
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of constitutive proteasome specific inhibitors have only been reported bound to the yeast 
proteasome.  
 Reported in this dissertation is the first structure of the human constitutive 20S 
proteasome, in both an unbound state and bound with the FDA approved proteasome 
inhibitor carfilzomib, which primarily targets the chymotrypsin-like site of constitutive 
proteasomes. The structure shows that carfilzomibs selectivity for the chymotrypsin-like 
subunits can be attributed to distinct van der Waals and hydrogen bonding interactions 
that are missing in the caspase-like (and to a lesser extent trypsin-like) subunits, as well 
as steric factors, such as 2His116 and Arg45 in the caspase-like site.  The P2 phenyl 
alanine of CFZ makes not contacts with the protein in any of the catalytic subunits, and it 
has been shown that substitution of methyl serine at the P2 position of CFZ demonstrates 
good oral bioactivity and is more resistant to microsomal degradation while maintaining 
low nanomolar potency [67]. Taken together, this provides evidence that the P2 substituent 
likely contributes to the drug’s overall pharmacological properties, but not to active site 
selectivity or to the IC50 values.  
 The P3 and P4 positions of CFZ, however, do appear to play a large role in active 
site selectivity. Interestingly, CFZ analogs truncated to be dipeptide epoxyketones only 
show weak potency (>1000 nM) against the chymotrypsin-like subunit, while tripeptide 
analogs maintain low nanomolar potency [67]. Additionally, comparison of our CFZ 
bound structure with the mouse constitutive proteasome:PR-957 complex reveals a new 
explanation for the drugs immunoproteasome selectivity. Similar structural 
rearrangements in the chymotrypsin-like subunits of constitutive proteasomes are caused 
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by both CFZ (which has a P1 leucyl group) and PR-957 (which has a P1 phenylalanine). 
The greater than 6-fold selectivity of CFZ for constitutive proteasomes, therefore, must 
reside outside the S1 pocket. Indeed, it was found that CFZ is able to make van der Waals 
interactions at the P3 and P4 positions, thereby regaining selectivity for the constitutive 
isoform. PR-957, on the other hand, binds to immunoproteasomes without structural 
rearrangements, however it lacks a P4 substituent and the alanine at P3 is insufficient for 
making van der Waals interactions, thus favoring immunoproteasomes for energetic 
reasons. These observations are further supported by the tripeptide epoxyketone inhibitor 
ONX0912 (PR-047), which also contains a phenylalanine side chain at the P1 position. 
Based on previous suggestions, a phenylalanine at the P1 position should favor binding to 
immunoproteasomes, however, the reported IC50 values indicate that it is two-fold more 
selective for the  constitutive chymotrypsin-like (IC50 = 36 nM (5c); 82 nM (5i)) [67]. 
This can now be explained based on the structures human proteasome:carfilzomib 
complex structure. Since PR-047 contains a methoxy group at the P3 position, it is suitable 
for making van der Waals interactions with the hydrophobic S3 pocket of chymotrypsin-
like subunits. Only a structure of the proteasome:PR-047 complex could indicate whether 
the N-terminal 2-methyl-1,3-thiazole cap is associated with the S4 pocket, which would 
also add favorable hydrophobic interactions, and in each case off-setting the structural 
rearrangement that is expected to occur in the S1 pocket.      
 The conservation of quaternary structure between the constitutive and 
immunoproteasomes, even across species, enabled a detailed look at the binding 
probabilities of carfilzomib to the human immunoproteasome catalytic subunits. 
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Carfilzomib is six times more selective for the chymotrypsin-like sites of constitutive 
proteasomes versus their immunoproteasome counterpart, and structural comparison with 
the mouse immunoproteasome indicates that the most profound difference is the 
conserved A27S substitution in the S3 pocket, diminishing its hydrophobic character, and 
making binding of the P3 leucyl less favorable.  PR-825, a structural analogue of PR-957, 
possesses a leucine at P1 and a methoxy-serine at the P2 and P3 positions. It has been 
shown to target constitutive chymotrypsin-like sites (5) with 20-fold the selectivity over 
immunoproteasome chymotrypsin-like sites, further supporting the hypothesis that non-
polar residues at P3 preferentially target constitutive chymotrypsin-like sites.   
 The proteasome remains an attractive target for antineoplastic drugs and the 
elucidation of the X-ray structure of the human constitutive CP provides the details 
necessary for it to serve as a useful tool in future drug development.  The use of CFZ in 
the clinic makes it imperative that the binding mode be well understood at the molecular 
level. The structures reported here will assist in the development of constitutive and 
immunoproteasome specific inhibitors, with therapeutic potential in cancer, autoimmune, 
and neurodegenerative diseases.   
 
3.4 Materials and Methods  
 
Purification and crystallization of unbound proteasome is described in sections 
2.3.1 and 2.3.2 respectively. For inhibitor bound structures, the proteasome crystals were 
soaked with carfilzomib at a final concentration of 5 mM in crystallization buffer, for 12 
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hours.  Carfilzomib was solubilized by sonication and vortexing prior to addition to the 
proteasome crystals. Crystals were then soaked in cryo-protecting buffer (30%MPD, 0.2M 
Sodium Formate) and flash frozen with liquid nitrogen prior to data collection. Data was 
collected using synchrotron radiation at the Advanced Photon Source (Argonne National 
Labs, IL) with = 0.97918 Å, at beam-lines 23iD and 19iD.     
 X-Ray intensities were indexed and scaled using HKL3000 [84] in the P21 space 
group. Carfilzomib bound crystals yielded 1177627 reflections, with 321261 being 
unique, and an overall completeness of 98.7%. Calculations of the Matthews coefficient 
using ccp4 [96] gave an approximate solvent content of 50%, assuming two core particles 
per asymmetric unit.. The phases were solved by molecular replacement using the default 
settings for the program Phaser [78] of the Phenix program suite [82], with the coordinates 
of the core particle from Bos Taurus (PDB ID 1IRU) as a starting model. A single solution 
was calculated and used for structure refinement.   
 Refinement of the carfilzomib bound structure was carried out in a similar manner 
as the unbound proteasome structure (section 2.3.3), using the program Phenix Refine 
version 1.82. The initial model obtained from molecular replacement was subjected to 
three rounds of  coordinate, restrained atomic displacement parameters (ADP), translation-
libration-screw-rotation (TLS), and occupancy refinement, however, 2-fold and 4-fold 
non-crystallographic symmetry (NCS) averaging (Cartesian) were used due to two-
molecules in the asymmetric unit. Real space refinement of the structure was carried out 
in COOT. A coordinate file (pdb file extension) for carfilzomib was built using the 
PRODRG server [113], and a crystallographic information file (CIF file) was generated 
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from eLBOW in Phenix. The carfilzomib structures were fit to the |Fo-Fc| density manually 
in COOT to each of the catalytic subunits (β1, β2, and β5), and all pdb files merged to 
form one pdb in COOT.  
Successive rounds of refinement in Phenix included custom geometry restraints of 
1.7 Å between the following proteasome:carfilzomib atoms: Thr1N:CBT, Thr1O:CBY, 
for each catalytic site with carfilzomib bound. The structure was refined to final Rwork and 
Rfree values of 0.22 and 0.25, respectively. Bond and angle values were 0.004 Å and 0.78
o, 
and the Ramachandran plot indicated that 96% of backbone dihedral angles were in 
allowed conformations.  The carfilzomib bound structure was deposited in the Protein 




4. DISCOVERY OF NOVEL PROTEASOME INHIBITORS; HIGH 
THROUGHPUT SCREENING 
 
4.1 Introduction   
  
Regulated protein turnover centers on the proteasome, and underlies a wide variety 
of signaling pathways, such as cell cycle control, transcription, and development [114]. 
Pharmacological inhibition of the proteasome can be efficacious in the treatment of human 
cancers, as proven by the FDA approved drugs bortezomib (Velcade, Millennium 
Pharmaceuticals) carfilzomib (Kyprolis, Onyx Pharmaceuticals), both used clinically for 
the treatment of multiple myeloma.  Additionally, several proteasome inhibitors are in 
clinical trials including Oprozomib (Onyx Pharmaceuticals, Inc.; ONX 1912; PR-047), an 
epoxyketone, which is being tested in phase 1b/2 clinical trials for the treatment of 
multiple myeloma, and a phase 1 study in patients with recurrent or refractory solid 
tumors. Marizomib (Nereus Pharmaceuticals) and ONX-0912 (Onyx Pharmaceuticlas) are 
β-lactone and epoxyketone proteasome inhibitors, respectively, and are each in phase 1 
clinical trials for the treatment of multiple myeloma.  
 Despite the success in developing proteasome inhibitors for use in the clinic, there 
are several draw backs to the current therapies. Bortezomib is known to cause peripheral 
neuropathy in patients due to off-target effects caused by its boronate warhead, which has 
moderate affinity for serine proteases, in particular HtrA2 [65].  Carfilzomib has poor 
bioavailability and a half-life of less than 30 minutes, which is inconvenient for patient 
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care. Drug resistance to bortezomib has been linked to an A49T mutation, which may 
disrupt hydrogen bonding and β-sheet formation with the inhibitors peptide backbone 
[115]. Additionally, both bortezomib and carfilzomib are substrates of p-glycoprotein 
which also leads to drug resistance due to the drug being pumped out of the cell. For these 
reasons there is a need to identify novel proteasome inhibitors with increased 
bioavailability, decreased side-effects, and capable of overcoming drug resistance which 
the current therapies are susceptible to. 
High throughput screening (HTS) is a drug discovery processes that is widely used 
in academia as well as industry, to quickly assay and identify potential drug-like 
compounds with biochemical activity. Normally, HTS is performed in microliter plates of 
96, 384 or 1536 well format. There have been arguments that HTS contributes to the 
decline in productivity of pharmaceutical companies, and suppresses the creativity of drug 
discovery [116, 117]. HTS success rates, however, are generally around 50% [118], and 
while all screening methods have their drawbacks, HTS offers a unique advantage  that it 
is applicable to a broader range of targets. Also, it is now understood that screening hits 
are simply chemical starting points that need to be optimized, and the expectation of 
identifying a drug directly from a screen has diminished.  
  Several HTS techniques have been successfully used in the laboratory to identify 
novel proteasome inhibitors, including virtual and in vitro screening [119], image-based 
screening [120], and high-content cell-based screening [121]. In the present thesis, we 
describe the use of a fluorescence based HTS assay, which relies on the cleavage of an 
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amino-methyl-coumarin tag (λex= 360nm, λem= 460nm) from a peptide substrate that is 
specific for the chymotrypsin-like site of the proteasome.  
Decrease in fluorescence compared to uninhibited proteasome was evaluated, and 
those compounds exhibiting greater than 80% inhibition were chosen for a secondary 
assay to verifying binding to the proteasome, as well as ensure that the decrease in 
fluorescence was not due to fluorescent quenching or other assay anomalies. The 
secondary assay utilizes a proteasome activity probe, Ada-Lys(biotinyl)-(Ahx)3-(Leu)3-
vinyl sulphone [122], which discriminates between compounds that are actually binding 
to the catalytic sites of the proteasome, and those compounds that give false positives in 
the HTS assay.  
 
4.2 Results and Discussion  
 
4.2.1 National Institute of Health Clinical Collection (NCC) 
   
The National Institute of Health’s Clinical Collection 2 (NCC) contains 450 
compounds which have a history of being used in human clinical trials. The plate was 
tested for inhibition against the chymotrypsin-like activity of the proteasome (Methods 
2.3.2). A positive hit was taken as 80% or greater inhibition at 10µM of test compound. 
Only one compound met the criteria, α-mangostin, resulting in a hit rate of 0.36%. The 
low hit rate was expected due to such a high threshold, however only potent proteasome 
inhibitors were of interest due to the nature of the plate being compounds that are known 
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to be clinically relevant, versus a fragment library for instance, in which we would set a 
lower threshold in the hopes of optimizing the hits as lead compounds.   
 The compound -mangostin is a natural product that can be isolated from the 
pericarp of mangosteens, a fruit found natively in Thailand (Figure 41). The fruit has a 
long history of medicinal use in both Chinese and Ayurvedic medicine. For centuries, 
people in Southeast Asia have used dried mangosteen pericarp for medicinal purposes; it 
is used as an antiseptic, an anti-inflammatory, an anti-parasitic, an antipyretic, an 
analgesic, and as a treatment for skin rashes [123].  
 Mangosteen has become a popular natural dietary health supplement, and the 
effects of mangosteen extracts have had recent scientific support. The characteristic anti-
proliferative effect of -mangostin has received a great deal of attention. It is shown to 
induce cell cycle arrest and apoptosis in colon [124], breast [125], prostate [126], and 
leukemia HL60 cells [127].  It has also been shown to inhibit cell invasion and migration 
in mammary and prostate cancer cells. Additionally, it is associated with down-regulation 
of matrix metaloproteinase-2 and-9, which are involved in disease processes such as 
arthritis and metastasis [128].  
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Figure 41 Chemical structure of -mangostin 
 
To determine the extent of in vitro inhibition of the individual catalytic sites of the 
proteasome, the IC50 value for α-mangostin was determined for each site; caspase-like 
(β1); trypsin-like (β2); or chymotrypsin-like (β5) (Methods 2.3). Concentrations of α-
mangostin were varied from 0-10 µM, and -mangostin was found to inhibit the 
chymotrypsin-like activity to the greatest extent (IC50 = 700 nM), followed by the caspase-
like activity (IC50 = 1.5 M) (Figure 45). No inhibition of the trypsin-like activity was 




Figure 42 In vitro inhibition of chymotrypsin-like and caspase-like activities of the 
proteasome by -mangostin. The IC50 values against the chymotrypsin-like and 
caspase-like activities were calculated to be 700 nM, and 1.5 M, respectively. Error 
bars represent standard deviations of triplicate experiments.  
  
To confirm the binding capability of -mangostin to each catalytic site of purified 
human 20S proteasome, α-mangostin was subjected to an in vitro binding assay utilizing 
the molecular probe, Ada-Lys(biotinyl)-(Ahx)3-(Leu)3-vinyl sulfone. The probe molecule 
consists of three parts: a “warhead” which covalently binds to the active site Thr1; a 
peptide linker which gives subunit specificity; and a visualization tag, biotin. The probe 
has comparable affinity (IC50 = 1M) for each of the three catalytic subunits of the 
proteasome (β1, β2, and β5) [122]. A control containing only enzyme and probe but no 
test compound was used in each trial. Additionally, a sample containing the known 
inhibitor bortezomib was used in each experiment as a positive control for binding. After 
thirty minutes the samples were run on an SDS PAGE gel, followed by Western blotting 
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with streptavidin alkaline phosphatase conjugated. Visualization by the addition of 
alkaline phosphatase substrate results in three bands on the membrane for no inhibitor 
control samples; one band for each catalytic subunit that has the probe bound. Bortezomib 
samples show no visible bands, due to blocking the binding of the probe.  
The binding assay confirmed that -mangostin was binding to both the 
chymotrypsin-like (5) and caspase-like (1) sites, while the trypsin-like site (2) 
remained uninhibited, interpreted by a dercrease in the band intensity for subunits β5/1 
but not β2 compared to the experimental control with no inhibitor (Figure 43).   
 
 
Figure 43 In vitro binding assay of -mangostin against human 20S proteasome. 
Lane 1 contains only proteasome and probe; lane 2 shows bortezomib as a positive 
control for probe binding; lane 3 is -mangostin. The diminished band intensities signify 
binding of inhibitor to the catalytic site indicated.  
  
 
To examine the cellular toxicity of α-mangostin, it was tested in a dose dependent 
manner against Molt4 Leukemia cells, as well as non-cancerous human dermal fibroblasts, 
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as described in Methods 2.6. The purpose of the fibroblasts is to establish whether α-
mangostin has general cytotoxicity, or if it is specific for cancer cells.   
The IC50 against the Molt4 leukemia cells was determined to be 15µM (Figure 44). 
Interestingly, the leukemia cells reached 100% cell death at 25µM, and showed 25% cell 
death at 12.5 µM (Figure 45), suggesting that toxicity occurs rapidly between these two 
concentration.  
Human dermal fibroblasts, on the other hand, showed no toxicity against α-mango 
at concentrations up to 50 µM (Figure 45). Bortezomib was used as a positive control for 
cell killing, and had an IC50 = 5µM. These results suggested that α-mangostin is selectively 
toxic against Molt4 Leukemia cells, while non-transformed cells remain unaffected.  
 
 





















Figure 45 IC50 Graph against human dermal fibroblasts 
 
To determine if α-mangostin targets the proteasome in intact Molt4  
Leukemia cells, the cell permeable activity based probe Ada-Lys(biotinyl)-(Ahx)3-
(Leu)3-vinyl sulfone was used  (Methods 2.5).  At concentrations of 50 µM, α-mangostin 
completely bound to all three catalytic sites of the proteasome, indicated by a diminished 
band intensity on the Western Blot compared to a no inhibitor control. At a concentration 
of 10µM of α-mangostin no binding was detectable by Western Blot (Figure 46).  Tannic 
Acid and and Enamine were used as a negative control to verify that 50µM of a random 
compound would not alter the expected band intensity leading to a misinterpretation of 
the blot. Carfilzomib was used as a positive control at a concentration of 10µM, and 
completely eliminated the Western Blot bands for all catalytic sites.  
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Figure 46 Western Blot Analysis of α-Mangostin in Molt4 Leukemia Cells. 
 
 
 In an attempt to determine the molecular basis for α-Mangostin’s proteasome 
inhibition, proteasome crystals were soaked with 5mM final concentration of α-Mangostin 
dissolved in crystallization buffer for 24 hours. X-ray data for the crystals were collected 
at Argonne National Labs and processed as described for the carfilzomib soaked crystals. 
The resolution extended to 3.0 Å, but unfortunately the difference electron density did not 
show the presence of α-mangostin in any of the catalytic subunits. This may be due to the 
low solubility of α-mangostin, as it was not completely dissolved during crystal soaking. 
Another possibility could be the low affinity, IC50 = 700 nM against the chymotrypsin-
like site, and longer crystal soaking times, or a higher concentration of α-Mangostin may 







4.2.2 Fungus Microbial Extracts; Zygophiala jamaicensis  
    
Microbial extracts from the fungus Zygophiala jamaicensis were fractionated by 
high performance liquid chromatography on a reverse phase C18 column, and a 1mL 
aliquot of each fraction placed into a separate well in a 96-well plates. These aliquots were 
subjected to high throughput screening against the chymotrypsin-like subunit of the 
human 20S proteasome (Section 2.3.2). One fraction demonstrated activity, so it was 
analyzed by liquid chromatography/mass spectrometry (LC/MS). LC/MS data was 
obtained for the active fraction on an Agilent 1200 Infinity series HPLC and an in-line 
Bruker micrOTOF-Q II mass spectrometer. The purified material was subjected to NMR 
spectroscopy by performing 1H, 13C, and Dr. Nishant Shetty assigned the structure based 
on the NMR data. It was determined to be a polyphenol, and therefore named PPH-1, for 
polyphenol-1 (Figure 48).   
 Similarly to α-mangostin, the IC50 value for PPH-1 was determined for each 
catalytic site of the proteasome, using concentrations of PPH-1 up to 100 µM. The 
chymotrypsin-like (β5) and caspase-like (β1) sites were each inhibited with an IC50 of  
15 µM (Figures 49 and 50, respectively), while no inhibition was seen against the trypsin-
like site (β2). Next, the in vitro binding assay was performed to validate PPH-1 as binding 
to the active sites. The western blot confirmed that PPH-1 does bind to the chymotrypsin-
like and caspase-like sites of the proteasome, and also indicated binding to the trypsin-like 
site, only to a lesser degree, interpreted by diminished band intensity (Figure 47). Due to 
the nature of the assay, quantitative information could not be obtained, and the binding to 
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the trypsin-like site is explained by the very high concentration of PPH-1 used for the 
assay, 100 µM.  
  
 
Figure 47 In vitro binding assay of purified human 20S proteasome. Lane 1 is a 
control with no inhibitor, only probe. Lane 2 had proteasome incubated with bortezomib 
prior to addition of probe. Lane 3 was proteasome incubated with PPH-1 prior to 
addition of probe. The diminished band intensities compared to lane 1 indicates binding 








Figure 49 In vitro enzymatic activity of PPH-1 against chymotrypsin-like activity. 
The IC50 against chymotrypsin-like site was determined to be 15 µM.    
 
Figure 50 In vitro enzymatic activity PPH-1 against caspase-like sites. The IC50 
against caspase-like sites was determined to be 15 µM.   
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 PPH-1 was also tested against a panel of cancer cell lines including; diffuse large  
B-cell lymphoma line CRL2631, breast cancer cell line MDA-MB-231, and ovarian 
cancer line OVCAR-3 (Figure 51). Cell lines were cultured in 384-well plates in the 
presence of PPH-1 at 13 different serial dilutions between 64 uM to 15.6 nM.  After 48 
hours resazurin was added.  Resazurin is a redox dye that is utilized to measure 
mitochondirial metabolism in live cells.  After overnight incubation with resazurin, plates 
were read at 570 nM in a POLARstar microplate reader. Graphs were plotted as percent 
of cell viability as compared to uninhibited cells, versus PPH-1 concentration. Although 
PPH-1 showed toxicity against the cell lines tested, similar toxicity was also observed 
against human dermal fibroblasts (data not shown). This suggests that although PPH-1 
inhibits the proteasome in vitro, there may be additional targets in intact cells which lead 
to a general toxicity.  
 In an attempt to determine the molecular basis for PPH-1’s proteasome inhibition, 
proteasome crystals were soaked with 5mM final concentration dissolved in crystallization 
buffer for 24 hours. X-ray data for the crystals were collected at Argonne National Labs 
and processed as described for the carfilzomib soaked crystals. The resolution extended 
to 3.0 Å, however, the difference electron density did not show the presence of PPH-1 in 
any of the catalytic subunits. This may be due to the high IC50 value of PPH-1, and higher 
concentrations during soaking, or longer soaking times, may be necessary to obtain a 
bound structure.  
 102 
 
Figure 51 Activity of PPH-1 against cancer cell lines. Cell lines tested were OVCAR 
3(ovarian cancer), MDA-MB-231(breast cancer), and multiple myeloma cell lines 2631, 
and G3.   
 
4.2.3 Lymphoma Hit Plate Screen  
  
The HTS lab at Texas A&M provided a “hit plate” of 313 compounds which show 
therapeutic potential against the multiple myeloma cell line 2631, and the drug resistant 
multiple myeloma cell line G3.  This was determined by dose response of the compounds 
against G3 in the presence of a typical therapeutic combination of CHOP 
(Cyclophosphamide, Hydroxydaunorubicin, Oncovin, and Prednisolone), and a dose 
response against 2631 in the absence of Chop. The greater the difference between the 
responses observed on the two cell lines was evaluated, and the top 2% were chosen for 
the “hit plate”. The compounds screened as candidates for the hit plate were from the Sac1 
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diversity library of the Sacchettini Research Group at Texas A&M. It contains compounds 
from ChemBridge and Enamine that generally have MW≤350 and cLogP≤3 which make 
them significantly more water soluble and less lipophilic. 
The compounds were screened at a final concentration of 10 µM against the 
chymotrypsin-like activity of the proteasome (Methods 2.3.2). A thresh-hold of greater 
than 80% inhibition was used and a total of 7 compounds were identified for a hit rate of 
2.2%. These hits are summarized in Table 3.  
 
Table 3 High Through-Put Screening Hits from Hit Plate  
Hit Plate Well Original Plate ID Original Plate 
Well 
Compound Structure 
C9 N1015-0161 A3 
 
D9 N1015-0162 H5 
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Hit Plate Well Original Plate ID Original Plate 
Well 
Compound Structure 
D18 EN36478-0016 E3 
 
E3 N1015-0005 B11 
 
E19 EN36478-0147 F5 
 
K19 EN36478-0173 H6 
 
Table 3 continued 
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Hit Plate Well Original Plate ID Original Plate 
Well 
Compound Structure 
L20 EN36478-0225 F3 
 
P15 CD00000081 C5 
 
 
 All seven hits were subjected to the secondary binding assay to ascertain if they 
were truly binding to the proteasome’s active site, or if they were false hits. False hits 
could be due to fluorescent quenching, precipitation, or other experimental anomalies. 
Bortezomib was used as a positive control for the binding assay which is shown in Figure 
53.  
None of the hits from the screen showed diminished band intensity compared to 
the no inhibitor control (Figure 52), indicating that none were binding to the active sites 
of the proteasome. While we cannot rule out that the hits may be inhibiting the proteasome 
Table 3 continued 
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allosterically, and therefore may not lead to diminished band intensity, because of the 
negative result in the binding assay,none of the hits were further pursued for 
crystallographic studies.    
 
 
Figure 52 Binding Assay for hit plate screen hits. Bortezomib (BTZ) was used as a 
positive control for inhibitor binding. None of the hits from the screen show diminished 
band intensity compared to the “no inhibitor” control, therefore they were not further 
pursued as possible proteasome inhibitors.  
 
4.3 Conclusions  
  
Since the identification of the proteasome as a target in cancer therapy, several 
approaches have been utilized for the identification of novel inhibitors, such as image-
based screening [120],virtual screening [129], and  high-content cell-based screening 
[121]. Additionally, novel proteasome inhibitors have been synthesized from a peptide 
core [122], based on structural data obtained from inhibitor complexes with the yeast 
proteasome.   
 Here, we show that utilization of a proteasome fluorogenic assay in a high 
throughput screening manner enabled the identification of two novel proteasome 
inhibitors, α-mangostin and PPH-1. Verification of binding to the proteasome active sites 
was confirmed with the molecular probe, Ada-Lys(biotinyl)-(Ahx)3-(Leu)3-vinyl 
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sulphone, and proves that screening with fluorogenic substrates can be a rapid method for 
identifying compounds with proteasome-inhibiting activity.  
 α-mangostin is a potent inhibitor of the proteasome in vitro, and was shown to  
bind to the proteasome in Molt4 leukemia cells, at a concentration which cell death occurs. 
The results do not, however, conclude that apoptosis is due to proteasome inhibition. 
Additional experiments must be designed that probe the exact manner and mechanisms of 
apoptosis for cell death in α-mangostin treated Molt-4 cells.   
 PPH-1 is a novel polyphenol with potent activity against purified human 20S 
proteasome. Polyphenols are structurally similar to many plant compounds, that have anti-
oxidant properties when taken orally (e.g. flavonoids such as quercetin; common in fruits 
and vegetables and shown in Figure 53), suggesting favorable bioavailability and low 
toxicity [130].  Also, compounds in this class are less likely to have activity against other 
cellular proteases, in contrast to most of the other peptide-based proteasome inhibitors.  
Polyphenols have been examined before for anti-cancer activity against a number of types 
of cancer [131].  For example, quercetin has been shown to lead to an an immediate 
inhibition of proteasomal activity in MCF7 and MDA-MB-453 breast cancer cell lines 
[132]. Additionally, epigallocatechin-3-gallate (EGCG) is in clinical trials as a treatment 
for chronic lymphocytic leukemia [133].   
 Polyphenols are known to have a number of liabilities as drugs.  For example, 
some have activity against other (non-protease) targets, such as receptor-tyrosine kinases 
[134].  Also, most polyphenols are eventually glucuronidated or otherwise metabolized, 
eventually leading to excretion [135]. Recently however, it has been shown that 
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peracetylation of the polyphenol proteasome inhibitor epigallocatechin-3-gallate (EGCG) 
(Figure 53), leads to a prodrug form of the compound [136].  The researchers suggested 
that esterase’s within the cellular milieu convert the prodrug back to its active form, and 
it was shown to be active against MDA-MB-231 breast cancer cells. These findings 
indicate therapeutic potential for prodrug forms of polyphenols, giving them potential to 
be used as either chemosensitizers to reduce the toxicity and boost the effectiveness of 
current chemotherapeutics such as bortezomib, or as stand-alone treatments.  
 
 
Figure 53 Structures of natural product polyphenol proteasome inhibitors.  
 
 Both -mangostin and PPH-1 are currently being subjected to crystallization trials 
so that their binding mechanism can be determined. In the case of α-mangostin, a detailed 
structural description would lead to a new class of proteasome inhibitors, as there are no 
similar proteasome inhibitor scaffolds described in the literature. While other polyphenol 
proteasome inhibitors are known, such as the above mentioned EGCG, there are no x-ray 
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structures to elucidate their binding modes either, therefore both structures could lead to 
an exciting new avenue of rational drug design against the proteasome.   
 
4.4 Materials and Methods  
 
4.4.1 Proteasome Fluorogenic Assay for Determination of IC50’s 
  
Proteasome activity and the inhibitory potency of ligands are routinely determined 
by fluorescence spectroscopy using active site specific AMC-peptides (7-Amino-
4methylcoumarin) as substrates [137]. For the determination of IC50 values of novel 
inhibitors, a 96-well Corning black round bottom black polystyrene micro-plate was used 
to carry out the assay.  
In each well, 50 ng of 20S proteasome, purified from human red blood cells 
(section 2.1), was incubated at 37 oC in assay buffer (20 mM Tris, pH 7.5, 50mM MgCl2), 
with inhibitor concentrations serial diluted per column, ranging from 0-100 µM. After 20 
minutes of incubation, the reaction was initiated by the addition of a fluorogenic substrate 
that was specific for the active site being probed (chymotrypsin-like, Suc-Leu-Leu-Val-
Tyr-AMC; trypsin-like, Boc-Leu-Arg-Arg-AMC; caspace-like, Z-Leu-Leu-Glu-AMC) 
(Boston Biochem).  The final substrate concentrations of 10 M, 20 M, and 20 M were 
used for chymotrypsin-like, caspase-like and trypsin-like active sites, respectively, and in 
each case the substrate was prepared in assay buffer from a 10mM DMSO stock. The rates 
of hydrolysis of the substrates were monitored using a POLARstar Omega micro plate 
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reader, with excitation/emission wavelengths of 360 nm/460 nm. The rates of hydrolysis 
can be directly correlated to the enzymatic activity of the proteasome. The reaction was 
monitored for 600 seconds, and the linear portion for each curve was used in calculating 
the IC50 values (inhibitor concentration to cause 50% inhibition of the enzyme active 
site).This was accomplished by plotting the residual proteasomal activity against the 
applied inhibitor concentration and fitting the experimental data to the equation: 
Y=Bottom + (Top-Bottom)/(1+10^((LogIC50-X)*HillSlope)) where X is the logarithm of 
inhibitor concentration and Y is the residual activity. Results are average of triplicate 
measurements.  
 
4.4.2 High Through-put Screening for Novel Proteasome Inhibitors 
  
Two test compound plates were obtained from the High Throughput Screening 
Lab (HTS) at Texas A&M University for use in the proteasome enzyme assay to identify 
novel inhibitors of the chymotrypsin-like activity. The first plate was the National Institute 
of Health’s Clinical Collection 2(NCC), which is a plate of approximately 450 small 
molecules that have a history of use in human clinical trials, according to the NIH website 
(www.nihclinicalcollection.com). The second plate obtained was made by the HTS 
facility and termed a “hit plate”. It is composed of 313 compounds which show therapeutic 
potential against the multiple myeloma cell line 2631, and the drug resistant multiple 
myeloma cell line G3.  This was determined by a dose response of the compounds against 
G3 in the presence of a therapeutic combination of CHOP (Cyclophosphamide, 
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Hydroxydaunorubicin, Oncovin, and Prednisolone), and a dose response against 2631 in 
the absence of Chop. The greater the difference between the responses observed on the 
two cell lines was evaluated, and the top 2% were chosen to be included in the “hit plate”. 
Additionally, Dr. Nishant Shetty of the Sacchettini Research group at Texas A&M 
University provided 1mL HPLC fractionated microbial extracts from the fungus 
Zygophiala jamaicensis, which were also tested for their inhibitory potency against the 
chymotrypsin-like site of the proteasome. Fractions that demonstrated greater than 50% 
inhibition were re-fractionated until a single agent causing the inhibition could be 
identified.   
In each case, 96-well Corning black round bottom polystyrene micro-plates were 
used for the assay. 50 ng of purified human 20S proteasome was incubated in assay buffer 
(20 mM Tris, pH 7.5) at 37 oC in the presence of 10 µM of test compound in each well, or 
0.5 µL of the microbial extract fraction. Reactions were initiated by the addition of 20 L 
of Suc-Leu-Leu-Val-Tyr-AMC in assay buffer, with a final concentration 50µM. The final 
reaction volume was 100 L and the reaction was monitored as described in section 
2.3.1.Compounds that showed greater than 80% inhibition compared to control (DMSO) 
wells (for NCC, and hit plate screen), were selected for an in vitro binding assay (Section 
2.4) as a secondary screen to verify the observed inhibition was due to inhibitor binding 
and not experimental error or anomalies, such as compound absorbance of the fluorescent 




4.4.3 In vitro Binding Assay  
  
Ada-Lys(biotinyl)-(Ahx)3-(Leu)3-vinyl sulphone is a synthetic proteasome 
inhibitor, which was designed by Kessler et al. to act as a “probe” for the proteasome’s 
catalytic sites [122], allowing a means to visualize via Western blotting whether or not a 
test compound has displaced the probe, thereby validating the compound as an inhibitor 
of that active site.  
The probe can be divided into three parts: a “warhead” ( in this case a vinyl 
sulphone) which covalently binds to the active site Thr1; a peptide linker which gives 
subunit specificity; and a visualization tag (biotin) which allows for analysis by Western 
Blotting with an appropriate antibody (streptavidin)(Figure 54). The probe has comparable 
affinity (IC50 = 1M) for each of the three catalytic subunits of the proteasome (β1, β2, 
and β5) [122]. 
 A control containing only proteasome and probe but no test compound was used 
in each trial to verify the presence of three distinct bands after Western Blotting. Subunits 
β1 and β5 have approximately the same molecular mass, therefor only two bands were 
visualized on the gels, with the lower band (indicative of β1/β5) appearing thicker than 
the β1 band. Additionally, a sample containing the known inhibitor bortezomib was used 
in each experiment as a positive control for binding. In the case that an inhibitor is present, 
the probe in unable to bind to Thr1, and the expected result is either decreased band 
intensity, or for the bands to be completely removed. 
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Binding assays were performed on test compounds which showed greater than 
80% inhibition against the chymotrypsin-like site of the proteasome during high 
throughput screening, and against the compound isolated from microbial extracts. The 
assay was  carried out at room temperature (23 oC) in 1.5 mL Eppendorf tubes.160 µg of 
purified human 20S proteasome was incubated with 50 µM of the test compound in 
reaction buffer (20 mM Tris pH 7.5, 50mM MgCl2). After thirty minutes, Ada-
Lys(biotinyl)-(Ahx)3-(Leu)3-vinyl sulphone (Enzo Life Sciences) was added at a final 
concentration of 1 µM to each sample and incubated on ice for 30 minutes. Next, 10µL of 
SDS loading buffer (10% w/v SDS, 10mM Dithiothreitol, 20% v/v glycerol, 0.2M Tris-
HCL, pH 6.8, 0.05% bromophenolblue w/v) was added to each sample, and the samples 
were run on an SDS-PAGE.  The protein was then transferred to a 0.45µm nitrocellulose 
membrane in transfer buffer (25mM Tris, pH 7.5; 192mM glycine; 20% methanol; 0.1% 
sodium dodecyl sulfate) for Western Blotting. The membrane was blocked overnight in 
6% milk extract in blotting buffer (20mM Tris pH 7.5; 1% NaCl; 0/1% Tween 20). After 
thoroughly washing the membrane with blotting buffer (three, fifteen minutes soaks of 
50mL), streptavidin, alkaline phosphatase conjugated (Sigma Aldrich) was added in 50mL 
of blotting buffer and 2% milk extract, to a final concentration of 1µg/mL and incubated 
with the membrane on a shaker for a minimum of 2 hours. The membrane was then washed 
three times with 50 mL of blotting buffer in 5 minute intervals, and protein bands 
visualized by the addition of 5mg of alkaline phosphatase substrate (Sigma Aldrich) 
dissolved in 10mL of water. Bands appeared within 60 seconds, and a diminished band 
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intensity compared to the control without inhibitor was considered positive for inhibitor 
binding to the active site.    
 
 
Figure 54 Proteasome binding probe. (Left) Schematic of the probe. (Right) Probe. 
 
 
4.4.4 Cell Based Binding Assay 
  
Binding of inhibitors to the proteasome in intact Molt4 Leukemia cells was 
determined using the same proteasome activity probe as described in section 2.4 (Ada-
Lys(biotinyl)-(Ahx)3-(Leu)3-vinyl sulphone). The probe is cell permeable, however, 
longer incubation times were necessary to allow for the inhibitors and the probe to each 
enter the cell and associate with the proteasome. Carfilzomib was used as a positive control 
for inhibitor binding.  
Molt4 Leukemia cells were graciously provided by Dr. Maxwell, Department of 
Biology, Texas A&M University. The cells were concentrated at 1.5 million cells per mL 
and 1mL aliquots were used per inhibitor being tested. The cells were incubated with either 
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10µM, or 50µM of inhibitor for 2 hours at 37oC. The final concentration of DMSO did 
not exceed 5%.  Controls of 5% DMSO and10µM Carfilzomib were used in each trial. 
After 2 hours of incubation, the molecular probe, Ada-Lys(biotinyl)-(Ahx)3-(Leu)3-vinyl 
sulphone, was added at a final concentration of 1µM, and the cells were incubated for an 
additional 2 hours at 37oC. The cells were then spun and pelleted at 1600 x G in a bench 
top Eppendorf 5702 centrifuge for 10 minutes. Cell pellets were re-suspended and lysed 
with 30µL of RIPA buffer (Sigma-Aldrich) on ice for 45 minutes. Lysate was centrifuged 
at 1600 x G for 10 minutes. Next, 10µL of protein loading dye was added to the 
supernatant, and the protein denatured at 100 oC. The entire supernatant was run on an 
SDS-PAGE gel. The protein was transferred to a 0.45µm nitrocellulose membrane in 
transfer buffer (25mM Tris, pH 7.5; 192mM glycine; 20% methanol; 0.1% sodium 
dodecyl sulfate) for Western Blotting. The membrane was blocked overnight in 6% milk 
extract in blotting buffer (20mM Tris pH 7.5; 1% NaCl; 0/1% Tween 20). After thoroughly 
washing the membrane with blotting buffer (three, fifteen minutes soaks of 50mL), 
streptavidin, alkaline phosphatase conjugated (Sigma Aldrich) was added in 50mL of 
blotting buffer and 2% milk extract, to a final concentration of 1µg/mL and incubated with 
the membrane on a shaker for a minimum of 2 hours. The membrane was then washed 
three times with 50 mL of blotting buffer in 5 minute intervals, and protein bands 
visualized by the addition of 5mg of alkaline phosphatase substrate (Sigma Aldrich) 
dissolved in 10mL of water. Bands appeared within 60 seconds, and a diminished band 
intensity compared to the control without inhibitor was considered positive for inhibitor 
binding to the active site.    
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4.4.5 Cell Based Toxicity Assays 
 
Cell based toxicity assays were performed by Dr. Kim Loesch at Texas A&M 
University, College Station, Texas. Human dermal fibroblasts (HDF) were purchased 
from ATCC (Manassas, VA).   HDF cells were cultured in DMEM (Lonza) media 
supplemented with 10% fetal bovine serum (Lonza) and penicillin/streptomycin (Lonza).  
Test compounds were serially diluted in phosphate buffered saline (PBS) plus 10% 
DMSO, starting from a maximum concentration of 100mM. HDF cells were trypsinized, 
counted with a Z1 particle coulter counter (Beckmann) and resuspended in media at a 
concentration of 64,000 cells/ml. Cells were then plated, over-laid with the inhibitor 
compound serial dilutions (0-100 µM), and incubated at 37oC.  After 48h, Resazurin dye 
(7-Hydroxy-3H-phenoxazin-3-one 10-oxide) was added and the assay plates cultured for 
an additional 24 hours. Resazurin is an oxidation-reduction indicator in cell viability 
assays. After 24 hours, the absorbance of the Resazurin was measured on a POLARstar 
Omega plate reader to assess cell death.  Cytotoxicity was determined as a percent of dead 
cells versus living.    
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5. DUAL PROTEASOME/FATTY ACID SYNTHASE INHIBITORS 
 
5.1 Introduction  
  
 The idea of hitting multiple cellular targets with a single drug, or 
polypharmacology, has emerged as a new concept for drug design by providing a single 
pharmacokinetic profile, rather than dosing in a “cocktail” fashion with two or more drugs. 
This strategy allows the design of compounds that purposefully affect multiple expressed 
targets [138].  The inhibition of multiple sites by a single drug decreases the likelihood 
that cancer or bacterial cells will develop resistance, due to the need to become resistant 
along multiple pathways; although, resistance by mechanisms such as drug pumps that 
remove the drug from the cell prior to it hitting its target, are still possible. The discovery 
process for polypharmacology drugs is serendipitous, and designing inhibitors aimed at 
multiple targets with predefined biological profiles is currently a great challenge for 
medicinal chemists. 
 There are many classes of proteasome inhibitors, depending on their C-terminal 
electrophilic group (Figure 55). One such class, are the beta-lactone containing natural 
and synthetic inhibitor, such as salinosporamide A which is in phase 1 clinical trials for 
the treatment of multiple myeloma, leukemia, and solid tumors [42]. Another beta-lactone 
containing proteasome inhibitor, belactosin C and its congener belactosin A, each possess 
similar inhibitory activity towards the chymotrypsin like activity of the proteasome (IC50 
= 0.2 µM). A recent X-ray study of the analog, N-CBz-O-Bn homobelactosin C, bound to 
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the yeast 20S proteasome, shows that the N-terminal Thr1 in the catalytic pocket of the 
proteasome is acylated by the beta-lactone moiety, confirming it as a proteasome inhibitor 
[139].   
 Fatty acid synthase (FAS), known to catalyze de novo lipid synthesis in the fatty 
acid biosynthetic pathway, is an attractive target for potential anticancer therapy. Found 
in most human carcinomas, including those of the breast and prostate, a high level of FAS 
expression and activity is one of the most prevalent changes to the metabolic network in 
human cancers [140]. FAS inhibition suppresses cell proliferation, adhesion, migration, 
and invasion. It also leads to suppression of genes involved in production of arachidonic 
acid and androgen hormones, both of which promote tumor progression [141]. Studies 
have shown that FAS inhibitors synergize with common anti-cancer therapies 
(Herceptin® and Taxol®) and in some cases reverse auto-resistance to those therapies, 
inhibit tumor angiogenesis (new vascularization), and may even act as a chemopreventive 
for cancer [142]. Healthy cells in the human body are not dependent on FAS activity, rather 
they take up and use dietary fats, rendering FAS an extremely intriguing therapeutic target.  
 Orlistat is a beta lactone containing compound in the reduced form of the natural 
product lipsatin. Being an anti-obesity agent by inhibiting pancreatic lipase, orlistat was 
approved by the FDA in 1999 as a prescription drug for obesity (Xenical®), and in 2007 
as the first over-the-counter weight-loss medication (Alli®). It was found recently that it 
inhibits the thioesterase (TE) domain of fatty acid synthase (FAS-TE, IC50 = 1.35 µM) 
and has antitumor activity [143]. X-ray analysis of the orlistat-human FAS-TE complex 
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reveals the covalent modification of the active site serine via acylation by the beta lactone 
[144].  
 The structural similarity between belactosins and orlistat prompted the research 
group of Dr. Romo at Texas A&M University to design a class of novel dual inhibitors 
which target both the 20S proteasome and FAS-TE. They synthesized a series of hybrid 
orlistat/ N-CBz-O-Bn homobelactosin C analogs, with the hypothesis that they would act 
as inhibitors of each enzyme. The hypothesis is based on the fact that belactosins and 
orlistat share a common pharmacophore in the form of a 2S,3S-bis-substituted beta 
lactone. The structural hybrids of these two classes of inhibitors could serve as dual 
inhibitors of both the proteasome and fatty acid synthase and could serve to overcome a 
major setback associated with anticancer chemotherapies targeting a single target; namely, 
mutations leading to loss of inhibition to a single target. . The first dual inhibitor YE-XO2 
was designed based on this and premise and is shown in Figure 56.  
 The crystallographic analysis of bis-benzylhomobelactosin C reveals that its di-
peptide side chains play a significant role in dictating which proteasomal active site will 
be targeted, via interaction with both the S1 specificity pocket and the primed substrate 
binding site [139]. Belactosins are the only class of proteasome inhibitors which bind to 
the primed region, whereas all other proteasome inhibitors bind to the nonprimed sites. 
The amide nitrogen of the C3-side chain of the inhibitor takes a position which blocks the 
nucleophilic addition of water, and in conjunction with the rings stereochemistry, forces 
the remainder of the C3-side chain into the primed site of the proteasome. Taking this into 
consideration, Dr. Romo’s group inserted the di-peptide into the hybrid design. Distinct 
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van der Waals and hydrophobic interactions are made between the ligand and residues in 
the primed site, and taking advantage of these interactions may lead to better in vitro 
potency. For example, compound KF33955, a benzyl ester derivative of belactosin A, that 
is presumably more cell permeable and exhibits greater growth inhibitory activity (IC50 = 
0.46 µM) toward HeLa S3 cells than belactosins A (IC50 = 51 µM) and C (IC50 = 200 µM) 
[145]. 
In addition, the crystal structure of FAS-TE bound with orlistat, revealed that the 
C1-C16-carbon skeleton of orlistat, termed the palmitic core, binds a predominately 
hydrophobic channel which they named the specifity channel [144]. Since both belactosin 
and orlistat possess a hydrophobic C3-side chain, Dr. Romo’s group used bis-benzyl 
homobelatocsin C together with orlistat as their lead compounds to design a dual inhibitor.   
The C2-hexanoyl chain of orlistat binds in the so-called short chain pocket. The 
mode of binding of belactosins, however, has not been explored for FAS; therefore, it is 
unknown what role the sec-butyl group or the C1’ stereocenter might play in enzyme 
selectivity for this class of inhibitor. Assuming that replacing the sec-butyl with a hexanoyl 
group will not impair the binding to 20S proteasome, they adopted the C2-side chain of 
orlistat in the initial dual inhibitors. To test this hypothesis along with YE-OX2 three 
additional analogs were designed which vary at the C2-side chain, including the one with 
a sec-butyl group. All the compounds were synthesized as mixtures of C2,C3-
diastereomers for ease of synthesis. These four compounds were tested for their ability to 
inhibit the 20S proteasome. 
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Figure 55 Proteasome and Fatty Acid Synthase Inhibitors. Orlistat (bottom right) 




Figure 56 Design of dual proteasome/fatty acid synthase inhibitors from orlistat 
and N-CBz-O-Bn homobelactosin C  
  
 
All four compounds were screened for percentage inhibition under the fixed 
concentration of 0.15 µM of the inhibitor (Table 4). All the compounds inhibited the 
proteasome at this concentration and the two most potent analogs, DR53 and DR60 
demonstrated similar potency to belactosin C (IC50 = 0.21 µM). The results indicate that 
the C2-side chain tolerates the modifications without significantly deteriorating the 
binding to the proteasome.      
These analogs and belactosin C were then screened for FAS-TE activity and the 
results are shown in Table 1. To our delight, all four new compounds were more potent 
than orlistat, with IC50 values ranging from 0.17 to 3.98 M. Interestingly, belactosin C 
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was more than 100 times less potent than DR33, indicating that its C3-side chain may 
enhance the binding to the specific channel of FAS-TE. Among the five compounds YE-
XO2 and DR33 are the most active. The less bulky C2-side chains of DR59 and DR53 
may provide fewer interactions in the short chain pocket, which may account for why 
DR59 and DR53 are more than 10 times less active than DR33 and YE-XO2 against FAS. 
 
Table 4 First Generation of Dual Proteasome/FAS Inhibitors  





(1.3:1 dr) DR33 
0.17 ± 0.04 
2 
 
(1.3:1 dr) belactosin C 
26.55 ± 0.07 
3 
 
(1:1 dr) DR59 
3.98 ± 0.63 
4 
 
(1:1 dr) DR53 
2.86 ± 1.75 
5 
 
(1:1 dr) DR60 (YE-XO2) 
0.16 ± 0.03 
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 The promising results of the first generation of dual inhibitors prompted Dr. Romo 
to pursue a second generation of dual inhibitors, which are presented in this thesis. The 
new inhibitors contain a di-peptide residue and a substituted betalactone with diversified 
stereocenters and substituents on C2 and C3. The whole molecule can be constructed by 
amide bond formation between di-peptides and carboxylic acids.  
 
5.2 Results and Discussion  
  
 Purified samples of each analog were graciously provided by Dr.Romo of the 
Department of Chemistry at Texas A&M University, College Station, TX. The analogs 
were subjected to enzymatic assays against all three catalytic activities of the proteasome 
(chymotrypsin-like, caspase-like, and trypsin-like) and against the theo-esterase domain 
of human fatty acid synthase (Methods section 2.3). The results of the assay are expressed 
as IC50 values and summarized in table 5.  
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All of the analogs were found to have a nanomolar or low micromolar affinity for 
the chymotrypsin-like subunits of the proteasome, with IC50 values ranging from 0.225 
M for MZ112 to 3.39 M against MZ400. Caspase-like subunits displayed IC50 values 
as low as 2.16 M for YE-XO2, however, no activity was seen against the trypsin-like 
subunits. Orlistat showed no activity against any of the proteasome active sites. 
  All analogs also had activity against FAS-TE which was comparable to the parent 
compound orlistat. The most potent was MZ112 with an IC50 value of 0.189 M, which is 
markedly reduced compared to orlistat which inhibited with an IC50 of 4.63 M.  
 The only difference in structure between I-a and I-c is that I-a has an alanine 
residue while I-c has a glycine residue. The Lack of a methyl group in I-c does not affect 
its proteasomal inhibitory activity, but makes it about 3 fold less potent against FAS. 
Replacing the terminus Cbz group of I-a with a bromobenzoyl group (I-f), conserves the 
hydrophobic interactions with the binding pocket and the potency was only slightly 
reduced. With one carbon spacer shorter than I-a (replacing L-ornithine with L-lysine), I-
h has slightly decreased activity against ChTL proteasome and FAS. Compound I-e has 
Table 5 continued 
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an alternative way of assembling the amino acids in comparison with I-a, in that the C2-
amino group of the lysine residue coupled with alanine. This altered linkage retains the 
activity and increases the specificity for the chymotrypsin like sites of the proteasome. 
The potency of I-e against FAS was doubled compared to I-a. Compound I-g has a closer 
structure to I-e, but has a more rigid di-peptide chain. The restricted flexibility did not 
have a large effect on the chymotrypsin-like activity, but reduced the specificity and the 
FAS-TE activity. Analogs I-i and I-j have the similar structure as I-e, but have extra 
substituents on the benzyl ring. The acetylene probe of I-j has slightly better 
chymotrypsin-like activity while maintaining selectivity. The increased polarity imparted 
by the methyl ketone group on I-i is likely the contributing factor for its reduced potency 
compared to I-e and I-j, which are presumably each able to make favorable hydrophobic 
interactions with the primed site and specificity channel of the proteasome and FAS, 
respectively.     
 In order to find out how the configuration on the β-lactone affects the activity, we 
tested analogs I-b and I-c that have reversed C2- and C3-stereogenic centers relative to 
naturally occurring belactosins. The change of the configurations in I-b decreased its 
proteasome activity by more than 2 fold compared to its diastereomer I-a, but slightly 
improved FAS activity. On the contrary, both the proteasome and FAS activity of I-d was 
reduced ~8 fold relative to the diastereomer I-e.  The results validated the importance of 
the configuration. The mismatched configuration probably makes the molecule fit poorly 
in the binding pocket. Crystallographic data of bisbenzylbelactosin C [139] reveals that 
once the molecule binds to the 20S proteasome and the Thr1Oγ-CO ester bond is formed, 
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the di-peptide side chain blocks the attack by water. As to I-b and I-c the reversed 
configuration at the beta lactone core probably disables the shielding of the di-peptide 
chain, so that the covalent binding is short-lived with reduced inhibition.     
  Replacing the C2-proton of I-a with a methyl group (II-a) impaired its ability to 
inhibit the chymotrypsin like sites of the proteasome.  The other two isomers II-b and II-
c followed the same trend of reduced potency. Even though the methyl group increased 
the stability of β-lactone in the medium during the assay process, the steric hindrance 
caused by the methyl group may impede the covalent attachment to ThrOγ of the 
proteasome.  
5.3 Conclusions  
 Polypharmacology has emerged as a new concept for drug design, based on the 
philosophy that one drug can hit multiple targets [146]. A drug with selective 
polypharmacology provides a single pharmacokinetic profile and potentially improves 
efficacy [138]. The inhibition of multiple sites makes the likelihood of the cancer cells 
developing resistance to the drug more difficult, due to the need to become resistant along 
multiple pathways.  
 There are several examples of polypharmacological drugs in the literature. 
Lapatinib, for instance, targets both EGFR and HER2 tryosine kinase, resulting in down 
regulation of thymidylate synthase [147], significantly inhibiting the proliferation of 
cancer cells both in vitro and in vivo [148]. Bromodomains, which have only recently been 
identified as druggable targets, show compelling rationale for the development of dual 
kinase-bromodomain inhibitors as therapeutics for both oncology and inflammatory 
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disease. For example, FLT3 receptor tyrosine kinase and BRD4 are both drivers in acute 
myelogenous leukemia (AML) [149, 150], JAK kinase and BRD4 inhibitors show 
complementary tumor and host microenvironment activities in multiple myeloma models 
[151], and both bromodomain and kinase inhibitors have shown compelling efficacy in 
inflammatory disease [152, 153].  
The structural similarity between the belactosin class of proteasome inhibitors and 
the fatty acid synthase (FAS) inhibitor orlistat, prompted the design of dual 
proteasome/FAS inhibitors. The orlistat analogs presented in this chapter show that 
potency is able to be maintained against FAS, while simultaneously showing nanomolar 
potency against the proteasome in vitro. Compounds I-e and II-a were also confirmed to 
have toxicity against the cervical cancer cell line HeLa with an IC50 of approximately 
40µM, and shown to target both 20S proteasomes and FAS in whole cells using activity-
based protein profiling (data not shown). Future experiments will be aimed at determining 
the complex structures of the orlistat analogs with the 20S proteasome and FAS, to allow 
for structure guided design of more potent inhibitors which may eventually lead to a 
clinically relevant drug.  
 
5.4 Materials and Methods  
 
The theo-esterase domain of human fatty acid synthase (FAS-TE) was tested 
alongside the proteasome for its ability to inhibit a series of tetrahydrolipstatin (orlistat) 
analogs, which were graciously provided by Dr. Daniel Romo of the Department of 
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Chemistry at Texas A&M University, College Station, TX (See Chapter 6). IC50’s against 
the three catalytic sites of the proteasome were determined in the same fashion as as 
described in section 4.4.1. 
Purified FAS-TE was provided by Dr. Romo at a stock concentration of 1mg/mL 
in 20mM Tris pH 7.5, 150mM NaCl, and 10% glycerol. The synthetic fluorogenic 
substrate for FAS-TE, 4-methylumbelliferyl heptanoate (4-MUH), was purchased from 
Sigma (St. Louis, MO).  The reaction mixture consisted of 500nM FAS- TE in buffer A 
(100mM Tris-HCl, 50 mM NaCl at pH 7.4) which was pre-incubated with 2.5 μL test 
compounds (orlistat or analog) dissolved in DMSO at final concentrations of 0.32-100 μM 
and/or 0.08-10 µM at 37 ºC for 30 minutes. The reaction was initiated by addition of 5 μL 
of 1.25 mM 4-MUH in 1:1 DMSO:buffer A.  The resulting fluorescence from liberated 4-
methylumbelliferone was measured every five minutes at 350ex/450emnm for 60 minutes. 
4-MUH auto cleaves without enzyme present; therefore, it was incubated without enzyme 
and served as a background control which was subtracted from all rates. Results are the 





 For over twenty years the proteasome has been an attractive target for the 
development of chemotherapeutic agents, due to being a critical regulator of cell growth 
and apoptosis. The X-ray structure of the T. acidophilum 20S proteasome was reported in 
1996 [19], and the first X-ray structure of Eukaryotic proteasomes was reported for S. 
cerevisiae in 1998 [21]. Additionally, the X-ray structures of the mammalian proteasomes 
for bovine [92], and mouse [16], have also been reported. As of June, 2014, there are over 
106 ligand complex structures with proteasomes entered in the protein data bank, none of 
which are the human proteasome.  
 Carfilzomib was granted FDA approval in 2012, and although the 
yeast:epoxomicin structure has been reported [61], carfilzomib contains different side 
chain substituents at the P2, P3 and P4 positions, and its binding to the 20S proteasome 
has not been described until now. The presented crystallographic analysis of the human 
constitutive 20S proteasome, alone and in complex with carfilzomib, emphasize the 
biological impact of distinct interactions in the substrate binding channel that influence 
the drugs selectivity not only among the different catalytic sites of constitutive 
proteasomes, but also immunoproteasome isoforms.  
 The presented x-ray structures do not, however, provide dynamic insights to the 
20S proteasome which may have substantial effect on substrate recognition, binding, and 
inhibition. It is interesting that both chymotrypsin-like and trypsin-like sites bind 
carfilzomib with very similar interactions. Both sites form six hydrogen bonding 
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interactions, one of which comes from D125 of the adjoining subunits. Additionally they 
each have hydrophobic S3 and S4 pockets that make van der Waals interactions with 
carfilzomibs side chains. While the S1 pocket of chymotrypsin-like sites requires 
structural rearrangements to accommodate carfilzomibs P1 leucyl group, trypsin-like sites 
are large and provide several van der Waals interactions without the need for movement. 
Therefore, based solely on the structural data, it would be tempting to think that tryspin-
like sites have better selectivity for carfilzomib; however IC50 values clearly show that 
chymotrypsin –like sites are 1000-fold better inhibited, highlighting the limitation of 
structural data on proteasome binding dynamics.   
 The importance of the interaction of the P1 site and the S1 pocket was 
demonstrated in the mouse constitutive and immunoproteasome crystal structures [16], 
however, the carfilzomib complex presented here shows that the S3 and S4 pockets play 
a critical role as well. While PR-957 has a bulky phenyl P1 side chain and preferentially 
targets immunoproteaome chymotrypsin-like sites, the epoxyketone oprozomib (ONX 
0912) also has a P1 phenyl but displays slight preference for constitutive proteasome 
chymotrypsin-like sites. This can be explained by the P3 methoxy serine which would 
form van der Walls interactions with the constitutive proteasome S3 pocket, but not the 
immunoproteaosme, which prefers small P3 residues such as alanine, because the 
conserved substitution A27S diminishes the size of the S3 pocket and adds polarity [16]. 
It would be interesting to see if changing the P3 substituent of the immunoproteasome 
specific inhibitors PR-957 and PR-924 from alanine to leucine would change their 
selectivity to favor constitutive proteasomes.  Additionally, adding a hydrophobic P4 
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residue to the immunoproteasome specific inhibitors may also shift their selectivity, due 
to the substitution of G48C which would act to electrostatically hinder binding to the S4 
pocket. 
Selective targeting of trypsin-like active sites has been accomplished with a 
peptide based inhibitor NC-022 that contain a P1 arginine and a P3 leucyl [38], which is 
favored by the large negatively charged S1 pocket and the hydrophobic S3 pocket. 
Caspase-like specific inhibitors such as NC-001[68] contains a P1 leucyl group and a P3 
proline. This carfilzomib bound proteasome structure presented shows that bulky residues 
at the P3 position sterically clash with H116 of the S3 pocket, possibly lending an 
explanation for NC-001 selectivity.  
The primary work undertaken in this thesis, the high-resolution crystal structure of 
carfilzomib in complex with the primary target, the human 20S proteasome, represents an 
important advance for the development of new inhibitor drugs, targeting not only the 
constitutive core particle, but also immunoproteasome core particles. This thesis provides 
a platform for a detailed description of binding mechanisms and optimization strategies 
for future therapeutics with potential applications for the treatment of cancer and 
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